Novel oxazolidinone based PPAR agonists: molecular modeling, synthesis and biological evaluation

Fresno, N.,^a Macías-González, M.,^{b,c,*} Torres-Zaguirre, A.,^a Romero-Cuevas, M.,^{b,c} Sanz-Camacho, P.,^a Elguero, J.,^a Pavón, J.,^{b,c} Rodríguez de Fonseca, F.,^{b,c} Goya, P.,^a Pérez-Fernández, R.^{a,d,*}

^aInstituto de Química Médica, IQM-CSIC, Juan de la Cierva, 3, E-28006 Madrid, Spain

^bCIBER Fisiopatología de la Obesidad y Nutrición. CB06/03. Instituto de Salud Carlos III, Madrid, Spain.

^cUnidad Gestión Clínica Endocrinología y Nutrición, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga. Hospitales Universitarios Regional y Virgen de la Victoria de Málaga, Universidad de Málaga, Spain.

^dCentro de Investigaciones Biológicas, CIB-CSIC, Ramiro de Maeztu 9, E-28040 Madrid, Spain.

KEYWORDS

oxazolidinone, PPAR agonists, molecular modeling, metabolic syndrome, diabetes

ABSTRACT

A series of new PPAR chiral ligands have been designed following the accepted three-module structure comprising polar head, linker and hydrophobic tail. The majority of the ligands incorporate the oxazolidinone moiety as a novel polar head, and the nature of the hydrophobic tail has also been varied. Docking studies using the crystal structure of an agonist bound to the LBD of the PPAR α receptor have been performed as a tool for their design. Suitable synthetic procedures have been developed and compounds with different stereochemistry have been prepared. Evaluation of basal and ligand induced activity proved that several compounds showed agonist activity at the PPAR α receptor, thus validating the oxazolidinone template for PPAR activity. In addition, two compounds **2** and **4** showed dual PPAR α / PPAR γ agonism, and interesting food intake reduction in rats.

1. INTRODUCTION

The peroxisome proliferator activated receptors PPARs are nuclear receptors activated by the binding of small lipophilic ligands either natural or synthetic. They can induce or repress genes modulating different biochemical processes such as adipogenesis, lipid and glucose metabolism, energy balance, and inflammation among others. Considered an important target in medicinal chemistry, significant efforts have been devoted to search new ligands capable of treating chronic disorders such as high levels of triglycerides, diabetes and metabolic syndrome and chronic inflammatory bowel disease.

There are three known subtypes of PPAR receptors: alpha (α), gamma (γ) and beta (β)/delta (δ). Whereas PPAR α is expressed in tissues with a high rate of fatty acid catabolism and modulates lipid metabolism and inflammation, PPAR γ is predominant in adipose tissue and

regulates glucose and lipid metabolism. Finally, the β/δ type is the most ubiquitous and has been the less investigated.¹

Despite intense research in developing PPAR ligands,² there are only few marketed drugs targeting PPAR α and PPAR γ and several promising candidates have failed in clinical trials (Fig.1). The α agonists, represented by fibrates (e.g. fenofibrate and gemfibrozil) are clinically used for the treatment of dyslipidemia. The thiazolidindiones (TZDs) or glitazones (e.g. pioglitazone) are considered as specific ligands for the γ receptor. They are being used for treating hyperglycemia in patients with type 2 diabetes. Due to the considerable structural homology between these PPAR isoforms, there are other kinds of dual ligands that bind to two or more isoforms. The most studied compounds under this description are the glitazars from which the saroglitazar (*S* enantiomer) has been recently approved and marketed under the trade name Lipaglyn as novel antidiabetic agent.³ Nowadays, there is a growing interest in developing dual PPAR α and PPAR γ agonists, since they may have fewer secondary effects compared to selective α and γ ligands.

Fig. 1. PPAR α and PPAR γ marketed drugs.

The PPAR receptors show however a high degree of stereoselectivity. The LBD (ligand binding domain) is responsible for ligand specificity and PPAR activation. The core of the Y-shaped LBD consists of a set of twelve antiparallel alpha helix (helix 1 to 12) and three-stranded antiparallel beta-sheet. The AF-2 domain located at the end of C-terminal helix 12 plays a critical role after ligand binding reducing the LBD flexibility and providing an appropriate interface for the cofactors recruitment. A large number of crystal structures of the PPAR-LBD with different ligands have been reported in literature enlightening a well-defined view of the agonists binding mode.⁴ In some cases chirality is a crucial point determining the PPAR binding mode and synthetic strategies to deal with these stereoselective issues have been recently reviewed.⁵ Laghezza *et al.* reported the 2-(aryloxy)-3-phenylpropanoic acids family with PPAR α/γ dual agonist activity. The (*S*) and (*R*) enantiomers of the isopropyl derivative were crystallized bound to the LBD of the receptor. The (*S*) stereoisomer behaved as a full and partial agonist of PPAR α and γ respectively.⁶ In 2002, α -substituted phenylpropanoic acid-type PPAR agonists were reported to bind to the LBD in different conformations indicating multiple binding points inside the binding pocket.⁷ Virtual screening approaches have also been described identifying and characterizing new PPAR γ scaffolds.⁸ Biological activity studies confirming these findings have not yet been reported.

The oxazolidinone is a five-membered heterocyclic ring with several applications as organocatalyst and chiral auxiliary (e.g. asymmetric aldol reactions).⁹ It is considered a valuable structural motif in medicinal chemistry.^{10, 11, 12} Oxazolidinones as chiral auxiliaries have been used by Miyachi and coworkers for the asymmetric synthesis of chiral α -acid derivatives as PPAR γ and α/γ ligands.^{13, 14, 15} On the other hand, *in vitro* metabolism studies of a PPAR γ ligand structurally similar to the oxazolidinone ring was reported by Agrawal *et al.*¹⁶

In this paper we describe 14 new PPAR chiral ligands¹⁷ mainly based on an oxazolidinone motif following the three-module structure described by Pirat *et al.*² A structure-activity relationship study was conducted by varying the hydrophobic tail and polar head. Moreover, compounds with different stereochemistry were synthesized in order to understand the PPAR binding mode. Docking studies were used as a tool to design these ligands. Some of these ligands showed interesting *in vitro* and *in vivo* pharmacological activities.

2. RESULTS AND DISCUSSION

According to the accepted model, the ligands bind through three chemical features: polar head, linker region and hydrophobic tail (Fig. 2).

In our case, the choice of the hydrophobic tail group was determined by the docking studies going from alkyl chains (alicyclic and cyclic) to aromatic rings trying to occupy the large hydrophobic cavity of the binding site. Besides, the hydrophobic aromatic linker with the appropriate length was introduced. Finally, a polar head such as the oxazolidinone ring or the carboxylic acid should enable the hydrogen bonds in front of the AF-2 helix to stabilize its conformation. The chirality in our ligands has been introduced either on the oxazolidinone ring (substituent in position 4, compounds **1-10**) or in the optically active (*S*)- α -acid (compounds **13**, **14**) or in both of them (**11**, **12**).

Fig. 2. PPAR chiral ligands general scheme and formulae.

2.1. Docking studies

Docking studies of two known PPAR agonists (GW409544, WY-1463) and compounds **2**, **3**, **4**, **7**, **8**, **9**, **10**, **13**, **14** were carried out by means of AutoDock v4 package. Table 1 summarizes the most stable conformations, the percentage of hydrogen-bonds with the hydroxyl group of Tyr464 (PPAR α) and Tyr473 (PPAR γ) of the 100 best docked conformations, the main polar interactions inside the LBD and the docking energy for the selected pose of each compound.

Table 1. Docking of compounds in the LBD of PPAR α and γ .

No.	Docking energy (kcal/mol)	Tyr 464 HB (%)	Polar interactions (PPAR α)	Docking energy (kcal/mol)	Tyr 473 HB (%)	Polar interactions (PPAR γ)
GW409544	-18.25	31	Ser280 Tyr314 Tyr464 His440	-14.45	23	Ser289 His323 Tyr473 His449
WY-14643	-8.99	63	Ser280 Tyr314 Tyr464			

			His440			
2	-10.68	4	Tyr314 Tyr464 His-40	-13.55	4	Tyr473 His449
3	-11.93	4	Tyr464 His440			
4	-11.54	12	Tyr464 His440	-11.1	3	Tyr473 His449
7	-12.24	3	Tyr314 Tyr-64 His440			
8	-13.33	13	Ser280 Tyr464 His440	-13.36	7	Ser289 His323 Tyr473
9	-10.85	2	Tyr464			

			His440			
10	-11.24	4	Tyr464 His440	-11.21	4	Tyr473 His449
13	-11.61	15	Ser280 Tyr314 Tyr464 His440	-11.08	7	Ser289 His323 Tyr473 His449
14	-9.99	22	Ser280 Tyr314 Tyr464 His440	-9.76	19	Ser289 His323 Tyr473 His449

The validation of the *in silico* model was performed comparing the X ray data of commercial compound GW409544 bound to the ligand domain of PPAR α (PDB:1K71) and to PPAR γ (PDB:1K74).¹⁸

According to the crystal structure, the aromatic rings of GW409544 established several interactions with non-polar amino acids of the PPAR α - LBD and PPAR γ - LBD. Additionally, GW409544 adopted a conformation within the receptor that allowed the carboxylate group to

form hydrogen bonds with Ser280, Tyr314, His440 and Tyr464 of PPAR α and Ser289, His323, His449 and Tyr473 of PPAR γ . These polar interactions and specifically the formation of hydrogen bonds with Tyr464 (PPAR α) and Tyr473 (PPAR γ) typically trigger a conformational change, notably in the activation function-2 (AF-2) helix, which aids in the recruitment of co-regulatory factors to regulate gene transcription.

For the PPAR α ligand binding domain, the AutoDock suite successfully reproduced the binding mode for GW409544, showing a root mean square deviation (RMSD) of one of the most stable binding conformations (pose #55) of 0.7 Å in comparison with the experimental geometry, and the same hydrogen bond patterns (Fig. 3A).¹⁹ An additional reference, the ligand WY-1463, which is the control ligand used in the *in vivo* tests, has also been included in the docking studies (Table 1).

The most stable docking solutions for the different ligands were analyzed, and the results suggest the existence of different potential binding modes of each compound onto the structure of the PPAR α -LBD. The hydrophobic tails of each compound were assigned to the same hydrophobic region occupied by the synthetic agonist GW409544 in the crystal structure of the PPAR α -LBD (Fig. 3).¹⁶ For these solutions, the oxazolidinone (CO) and carboxylic acid polar groups were close to the hydroxyl group of the lateral chain of Tyr464, which donated a hydrogen bond. The binding modes were stabilized by the hydrogen bond network with: Tyr314, Tyr464 and His440 (**2**, **7**), Tyr 464 and His440 (**3**, **4**, **9** and **10**), Ser280, Tyr464 and His440 (**8**) and with the four residues just compounds **13** and **14**. Nevertheless, some divergences can be found in the percentage of hydrogen bonds with the hydroxyl group of the Tyr464 residue. The chirality induced by the substituent attached to the oxazolidinone ring in position 4 is responsible for the orientation of the CO group towards the polar residues. For instance, enantiomers **2** and **8**

showed some differences in the percentage of hydrogen bond with Tyr464 and in the polar residues interactions. However, at this point, in the absence of crystallization data, these results must be considered as a theoretical approximation.

Fig. 3. Docking representation of best location/orientation binding modes. Docking representation of best location/orientation binding modes of GW409544 pose #55 (A), **2** pose #62 (B), **14** pose #3 (C) and **8** pose #4 (D) in balls and sticks colored by atom type. The co-crystallized conformation of GW409544 is shown in green and the protein backbone by ribbons (blue). The most important polar interactions (dashed green lines) and residues involved are shown (Ser280, Tyr314, His440 and Tyr464). All agonist compounds form a hydrogen bond with Tyr464.

In the case of PPAR γ -LBD, docking studies were carried out with **2**, **4**, **8**, **10**, **13** and **14**. The hydrophobic tails of these compounds were assigned to the same hydrophobic region occupied by the synthetic agonist GW409544 in the crystal structure of the PPAR γ -LBD, whereas the polar heads of the compounds were involved in a hydrogen bond network with the following residues (*i.e.*, Ser289, His323, His449 and Tyr473). Docking representations of the structures of compounds **2** and **4** onto the PPAR γ -LBD are represented in Fig. 4.

Fig. 4. Docking representation of best location/orientation binding modes to PPAR γ -LBD of GW409544 pose #3 (A), **2** pose #4 (B), **4** pose #31 (C) in balls and sticks colored by atom type. The co-crystallized conformation of GW409544 is shown in green and the protein backbone by ribbons (blue). The most important polar interactions (dashed green lines) and residues involved are shown (Ser289, His323, Tyr473, and His449). All agonist compounds form a hydrogen bond with Tyr473.

2.2. Chemistry

For the preparation of compounds **1-10** we followed the synthetic strategy depicted in Scheme 1.

Reagents: i) Boc_2O , Et_3N , dioxane/ H_2O (2:1), r.t., 24h (89%); ii) coupling agent, HOBt, Et_3N , R-NH_2 , solvent, r.t., 12h (31-84%); iii) $\text{CH}_2\text{Cl}_2/\text{TFA}$ (1:1), r.t., 12h (80-92%); iv) $^t\text{BuOK}$, Methyl 3-(bromomethyl)benzoate, THF anh., r.t., 7h (62%); v) $\text{Al}(\text{CH}_3)_3$, THF, mw, 125°C , 20min (40-50%); vi) Methyl 3-(bromomethyl)benzoate, Cs_2CO_3 , THF anh./ CH_3CN anh. (1:1), r.t. 6h (66%); vii) **17**, $\text{Al}(\text{CH}_3)_3$, THF, mw, 125°C , 20min (80-89%).

Scheme 1. Synthesis of compounds **1-10**.

The key intermediate **17** was synthesized in three steps. Starting from commercially available 4-aminobenzoic acid, protection of the amine with Boc anhydride provided **15**. Amide bond formation between the carboxylic group of **15** with several amines (Fig. 1) using EDCI or PyBOP gave intermediate **16** in moderate yields. The *tert*-butyl carbamate **16** was cleaved under anhydrous acidic conditions giving **17** in good yields. The oxazolidinone motif was incorporated after a two-step synthesis starting from the commercially available (*R*)-4-benzyl-3-propionyl-2-oxazolidinone in the case of compounds (**1-7**) and from the (*S*)-4-benzyl oxazolidinone for

compounds (**8-10**). In the first case, the use of ^tBuOK at room temperature triggered a cross-alkylation reaction in which the oxazolidinone anion attacked the benzyl bromide derivative as we have recently reported, providing the oxazolidinone derivative **18** in moderate yields.²⁰ In the second case, the alkyl halide underwent a nucleophilic substitution under basic conditions giving the (*S*)-4-benzyl oxazolidinone derivative **19**. The final step to obtain compounds (**1-10**) involved a microwave-assisted amide bond formation between an ester (**18**) or (**19**) and various amine derivatives (**17**) mediated by a trimethyl aluminium complex.

The synthesis of compounds **11-14** is summarized in Scheme 2. For these compounds, two different hydrophobic tails were selected: the *p*-*tert*-butylbenzyl and the butyl one. Intermediate **21** was synthesized in two steps starting from commercially available methyl *p*-*tert*-butylphenylacetate or methyl hexanoate, an amide bond formation with the two different amines followed by the acid conversion to acyl chloride gave **21** in moderate yield.

The second fragment of this synthesis (compound **23**) is obtained in two steps. First, an Evans' asymmetric alkylation in which the (*R*)-4-benzyl-3-propionyl-2-oxazolidinone was treated with 3-nitrobenzyl bromide under Evans' protocol (NaHMDS at -78 °C) provided **22**. Secondly, a Palladium-catalyzed reduction of the aromatic nitro group to amine gave **23** in good yield.

Compounds **11** and **12** resulted from the amide bond formation between the acyl chloride **21** and the amine derivative **23**. Then, a hydrogenolysis of the oxazolidinone ring using LiOH/H₂O₂ gave the chiral acid derivatives in alpha position, compounds **13** and **14**.

Reagents: i) 4-aminobenzoic acid, $\text{Al}(\text{CH}_3)_3$, THF, mw, 125°C, 20min (65-70%); ii) SOCl_2 , THF, 80°C, 6h; iii) NaHMDS, THF anh., 3-nitrobenzyl bromide, -78°C, 6h (70%); iv) $\text{H}_2/\text{Pd-C}$, THF/EtOAc (1:2), 21 psi, r.t., 12h (90%); v) **21**, THF, r.t., 12h, (34-68%); vi) LiOH, H_2O_2 , 0°C-r.t., 6h, (62-70%).

Scheme 2. Synthesis of compounds **11-14**.

2.3. Pharmacology

Luciferase reporter gene assays were performed with extracts from MCF-7 cells that were transiently transfected with a reporter construct containing four copies of the human CPTI DR1-type RE (for PPARs) and the indicated expression vectors for PPAR α , RXR α , NCoR (CoR). Cells were treated for 16 h with 10 μM of different compounds: DMSO (solvent), the reference PPAR α agonist GW7647, the endogenous PPAR α agonist OEA, the reference PPAR γ

1
2
3 Rosiglitazone, and compounds 1 to 14. MD Simulation of luciferase activity was normalized to
4 the basal activity of PPAR α -RXR α -SRC1 in the presence of the solvent (DMSO). Details on the
5 methodology have been published previously.^{21,22,23,24,25}
6
7

8
9
10 Compounds 2, 4, 5, 6, 8, 11, 12, 13 and 14 showed agonist activity at the PPAR α receptor.
11
12 Among them, compounds 2 and 4 displayed moderate agonism at the PPAR γ receptor so they
13 may be considered as interesting dual PPAR α/γ agonists. These compounds also showed key
14 important interactions in the docking studies with both PPAR isoforms. Flexibility in the
15 hydrophobic tail is desired (4) over rigid hydrogenated rings (7) in accordance with the
16 performed docking studies. The (*R*) stereochemistry at the oxazolidinone ring is preferred over
17 the (*S*) one, and the oxazolidinone ring choice as polar head with a shorter linker resulted to be
18 slightly better than the existing one in compounds 11 and 12. On the other hand, a difference of
19 one order of magnitude in activity was observed between the carboxylate polar head of 14 and
20 the oxazolidinone ring in 12 with the same hydrophobic tail and linker. This fact correlates
21 perfectly with the docking studies where the (*S*)- α acid derivative showed interactions with all
22 the key residues at the LBD and a high HB percentage with Tyr464. As we can observe from the
23 *in vitro* and docking results, interactions with the polar residues are important but in some cases
24 flexibility and length of the ligand compensate the loss of HB with the polar residues in the LBD.
25 This could explain why smaller ligands like (*R*)-oxazolidinone 2 show similar *in vitro* results to
26 (*S*)- α acid 13.
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

48 For the *in vivo* studies we selected compounds 2 and 4 since they behaved as dual agonists
49 with interesting PPAR α EC₅₀ values and moderate affinity for PPAR γ isoform.^{19,26} In
50 *in vivo* pharmacology was tested using the model of feeding behavior in food deprived animals, that
51
52
53
54
55
56
57
58
59
60

provides a good screening test for PPAR alpha agonists with efficacy in animal models of obesity and metabolic disorders.

Table 2. Pharmacological properties of compounds **1-14**.

No.	PPAR α activation EC ₅₀ (nM)	PPAR γ activation EC ₅₀ (nM)
OEA	152 $\pm$ 31	-
GW7647	65 $\pm$ 1	-
Rosiglitazone	-	870 $\pm$ 11
1	>10 ⁻⁴ M	>10 ⁻⁴ M
2	670 $\pm$ 157	1298 $\pm$ 261
3	>10 ⁻⁴ M	>10 ⁻⁴ M
4	821 $\pm$ 139	1622 $\pm$ 388
5	6623 $\pm$ 1232	>10 ⁻⁴ M
6	1978 $\pm$ 213	-
7	>10 ⁻⁴ M	>10 ⁻⁴ M
8	756 $\pm$ 125	-
9	>10 ⁻⁴ M	-
10	>10 ⁻⁴ M	-
11	966 $\pm$ 233	-
12	1922 $\pm$ 408	-
13	866 $\pm$ 188	-
14	981 $\pm$ 476	-

EC₅₀ values calculated in the presence of the different compounds by GraphPad Prism 4. Results are the mean $\pm$ SEM. of 3 experiments.

In vivo food intake studies

The acute administration of compound **2** induced a dose-dependant reduction of food intake in adult obese male rats that had been deprived of food for 24 h. Compound **2** at the effective dose of 3.0 mg/kg is able to reduce food intake around 50% being active up to 120 min. This effect disappears after 240 min (Fig. 5).

Fig 5. Feeding inhibition induced by acute administration of compound **2**. Time course of the inhibition of food intake induced by **2** at doses of 0.3, 1.0 and 3.0 mg/kg. The compound is active up to 120 min after administration (0'-60', $P < 0.05$; 60'-120', $P < 0.05$). Abscissa represents time (min) while the ordinate axis represents the cumulative food intake (mg/kg).

The acute administration of compound **4** induced a dose-dependant reduction of food intake at the effective doses of 1.0 and 3.0 mg/kg (Fig. 6). This compound remained active 240 min after dosing and surprisingly it continued exerting its effect 24 h later. Therefore, compound **4** is an interesting candidate for chronic administration studies (Fig. 7).

Fig 6. Feeding inhibition induced by acute administration of compound **4**. Time course of the inhibition of food intake induced by **4** at doses of 0.3, 1.0 and 3.0 mg/kg. The compound is active up to 240 min after administration at 1.0 mg/kg (0'-240', $P < 0.01$) and at 3.0 mg/kg (0'-30', $P < 0.0001$; 30'-120', $P < 0.001$; 120'-140', $P < 0.01$). Abscissa represents time (min) while the ordinate axis represents the cumulative food intake (mg/kg).

Fig 7. Feeding inhibition results 24 h after compound **4** administration. The compound **4** at 1.0 mg/kg ($P < 0.01$) remained active over 24 h after dosing in a dose-dependent manner. Abscissa represents time (24 h) while the ordinate axis represents the cumulative food intake (mg/kg).

1
2
3 In summary, based on molecular modeling and docking studies we have prepared novel PPAR
4
5 ligands incorporating an oxazolidinone ring. Pharmacological assays, both *in vitro* and *in vivo* of
6
7 these chiral PPAR ligands have shown that the oxazolidinone motif is an interesting structural
8
9 feature for PPAR activity. The easy way to synthetically reach these compounds and to perform
10
11 structural modifications make them interesting leads for further development. Two of them
12
13 (compounds **2** and **4**) can be considered as dual well-balanced PPAR α/γ ligands. Furthermore,
14
15 they have shown interesting *in vivo* properties that make them attractive candidates for further
16
17 research in the treatment of metabolic syndrome.
18
19
20
21
22
23
24

25 3. EXPERIMENTAL SECTION

26 **Chemistry. General methods**

27
28 All chemicals were purchased from commercial suppliers and used without further
29
30 purification. TLC: precoated silica-gel 60 254 plates (Merck), detection by UV light (254 nm).
31
32 Flash-column Chromatography (FC): Kieselgel 60 (230–400 mesh; Merck). Melting points (mp)
33
34 were determined in open capillaries with a Gallenkamp capillary melting-points apparatus. ^1H
35
36 and ^{13}C NMR spectra were recorded on Bruker Advance 300 spectrometer operating at 300.13
37
38 MHz and 75.47 MHz respectively, in CDCl_3 or $\text{DMSO}-d_6$ as solvents. Chemical shifts are
39
40 reported in ppm on the δ scale. In the case of multiplets, the signals are reported as intervals.
41
42 Signals were abbreviated as s, singlet; d, doublet; t, triplet; and m, multiplet. Coupling constants
43
44 are expressed in hertz. Hydrogenation reactions were carried out in a Shaker type hydrogenation
45
46 apparatus (Parr). Elemental analysis was determined with a LECO Elemental Analyzer CHNS-
47
48 932. LC-MS analyses were performed using an Alliance 2695 (Waters) with a diode array
49
50 UV/Vis detector Waters 2996 and interfaced to a Micromass ZQ mass spectrometer. Analyses
51
52
53
54
55
56
57
58
59
60

were performed using reversed phase HPLC silica based columns: column Bridge C18 3.5 mm. (2.1 x 100 mm). Using an injection volume of 3 mL, a flow rate of 0.25 mL/min and gradient elution (15 to 95 % over 10 min) of acetonitrile in water. Acetonitrile contains 0.08% v/v formic acid and water contains 0.1% v/v formic acid. Analyses were monitored at 254 nm wavelength. Flash chromatography was performed using a Biotage IsoleraTM flash purification system.

General Procedure for the Synthesis of 1-10. To a solution of **18** or **19** (1 Eq) and the corresponding amines (2 Eq) in dry THF, it was added Al(CH₃)₃ in heptane 2.0 M (2 Eq). The mixture was heated at 125 °C for 35 min in a microwave reactor. The reaction mixture was poured into an erlenmeyer, cooled in an ice bath and 1 N HCl aqueous solution was slowly added until the effervescence ended. The mixture was taken to an extraction funnel and Et₂O was added. The residue was purified by flash chromatography.

(R)-3-[(4-benzyl-2-oxooxazolidin-3-yl)methyl]-N-[4-(benzylcarbamoyl)phenyl]benzamide (1). Compound **18** (0.06 g, 0.18 mmol), compound **17a** (0.08 g, 0.36 mmol), Al₃(CH₃)₃ in heptane 2.0 M (0.2 mL, 0.36 mmol) in THF (10 mL) were heated at 125 °C for 35 min in a microwave reactor. The residue was purified: Biotage KP-Sil 25g, EtOAc/Hexane from (5:95) up to (10:90) yielding a white solid (0.04 g, 40 %). M.p. 120 °C. ¹H NMR (300 MHz, DMSO-*d*₆) δ (ppm) 10.47 (s, 1H, NH), 8.95 (t, *J* = 6.0 Hz, 1H, NHCH₂), 8.04 – 7.78 (m, 6H, H-Ar), 7.64 – 7.48 (m, 4H, H-Ar), 7.45 – 7.13 (m, 8H, H-Ar), 4.68 (m, 1H), 4.47 (d, *J* = 6.0 Hz, 2H, NHCH₂), 4.41-4.31 (m, 1H), 4.22 (m, 1H), 4.08 – 3.99 (m, 1H), 4.03 – 3.83 (m, 1H), 3.05 (dd, *J*_{ab} = 13.5, *J*_{a4} = 4.2 Hz, 1H), 2.75 (dd, *J*_{ba} = 13.5, *J*_{b4} = 8.2 Hz, 1H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ (ppm) 165.6 (CO), 165.5 (CO), 158.6 (C), 139.8, 137.3, 136.1, 135.1, 135.5, 131.0, 129.2 (2C), 128.7, 128.5 (2C), 128.2 (3C), 127.9 (2C), 127.2 (3C), 126.8, 126.7 (2C), 119.5 (2C), 66.3 (C), 55.3

(C), 45.1 (C), 42.5 (CH₂), 37.2 (C). HPLC/MS: gradient elution (40 to 95 % over 10 min) of acetonitrile in water, retention time 4.61 min [M+H]⁺ = 520. Elemental analysis calcd. for C₃₂H₂₉N₃O₄: C, 73.97; H, 5.63; N, 8.09; found C, 73.88; H, 5.66; N, 8.08.

(R)-3-[(4-benzyl-2-oxooxazolidin-3-yl)methyl]-N-[4-((4-*tert*-butyl)benzyl)carbamoyl]phenyl]benzamide (2). Compound **18** (0.06 g, 0.18 mmol), compound **17b** (0.08 g, 0.36 mmol), Al(CH₃)₃ in heptane 2.0 M (0.2 mL, 0.36 mmol) in THF (10 mL) were heated at 125 °C for 35 min in a microwave reactor. The residue was purified: Biotage KP-Sil 25g, EtOAc/Hexane from (5:95) up to (10:90) yielding a white solid (0.05 g, 44 %). M.p. 110 °C. ¹H NMR (300 MHz, CDCl₃) δ (ppm) 8.91 (s, 1H, NH), 7.83-7.80 (m, 1H, H-Ar), 7.78 – 7.63 (m, 5H, H-Ar), 7.44 – 7.15 (m, 9H, H-Ar), 7.07 – 6.96 (m, 2H, H-Ar), 6.66 (t, *J* = 5.7 Hz, 1H, NHCH₂), 4.74 - 4.65 (m, 1H), 4.57 (d, *J* = 5.4 Hz, 2H, NHCH₂), 4.21 – 4.07 (m, 2H), 4.00 – 3.90 (m, 1H), 3.87 – 3.76 (m, 1H), 3.04 (dd, *J*_{ab} = 13.6, *J*_{a4} = 4.8 Hz, 1H), 2.63 (dd, *J*_{ba} = 13.6, *J*_{b4} = 8.5 Hz, 1H), 1.30 (s, 9H, 3CH₃). ¹³C NMR (75 MHz, CDCl₃) δ (ppm) 166.8 (CO), 165.8 (CO), 158.6, 150.5, 141.2, 139.7, 136.5, 135.2, 131.2, 129.8, 129.2, 128.9 (2C), 128.9 (2C), 127.9 (2C), 127.7 (2C), 127.2, 127.1, 126.6, 125.6 (2C), 119.9 (2C), 67.1 (C), 55.8 (C), 46.0 (C), 43.8 (CH₂), 38.6 (C), 34.5 (C(CH₃)₃), 31.3 (3CH₃). HPLC/MS: gradient elution (40 to 95 % over 10.0 min) of acetonitrile in water, retention time 8.83 min [M+H]⁺ = 576. Elemental analysis calcd. for C₃₆H₃₇N₃O₄: C, 75.11; H, 6.48; N, 7.30; found C, 75.00; H, 6.75; N, 7.70.

(R)-3-[(4-benzyl-2-oxooxazolidin-3-yl)methyl]-N-[4-((4-(trifluoromethyl)benzyl)carbamoyl]phenyl]benzamide (3). Compound **18** (0.1 g, 0.31 mmol), compound **17c** (0.18 g, 0.61 mmol), Al(CH₃)₃ in heptane 2.0 M (0.3 mL, 0.61 mmol) in THF (10 mL) were heated at 125 °C for 35 min in a microwave reactor. The residue was purified: Biotage KP-Sil 25g, EtOAc/Hexane from (5:95) up to (10:90) yielding a white solid (0.09 g, 50 %). M.p.

114 °C. ¹H NMR (300 MHz, DMSO-*d*₆) δ (ppm) 10.49 (s, 1H, NH), 9.07 (t, *J* = 6.1 Hz, 1H, CH₂NH), 7.98 – 7.77 (m, 6H, H-Ar), 7.69 (m, 2H, H-Ar), 7.53 (m, 5H, H-Ar), 7.35 – 7.10 (m, 4H, H-Ar), 4.68 (d, *J* = 15.6 Hz, 1H) 4.55 (d, *J* = 5.8 Hz, 2H, CH₂NH), 4.41 (m, 1H), 4.22 (m, 1H), 4.04 (m, 1H), 3.92 (m, 1H), 3.05 (dd, *J*_{ab} = 13.5, *J*_{a4} = 4.2 Hz, 1H), 2.75 (dd, *J*_{ba} = 13.6, *J*_{b4} = 8.1 Hz, 1H). ¹³C NMR (75 MHz, DMSO) δ (ppm) 165.8 (CO), 165.7 (CO), 157.7 (C), 144.7, 141.9, 139.2, 137.3, 136.1, 135.1, 131.0, 129.2 (2C), 129.0, 128.7, 128.5 (3C), 128.0 (2C), 127.9 (3C), 127.85, 127.6, 126.8, 126.7, 125.2, 119.5, 66.3 (C), 55.3 (C), 45.1 (C), 42.3 (NHCH₂), 37.2 (C). HPLC/MS: gradient elution (40 to 95 % over 10.0 min) of acetonitrile in water, retention time 10.2 min [M+H]⁺ = 588. Elemental analysis calcd. for C₃₃H₂₈F₃N₃O₄: C, 67.45; H, 4.80; N, 7.15; found C, 67.69; H, 5.00; N, 7.14.

(*R*)-3-[(4-benzyl-2-oxooxazolidin-3-yl)methyl]-*N*-[4-(pentylcarbamoyl)phenyl]benzamide

(4). Compound **18** (0.10 g, 0.31 mmol), compound **17d** (0.13 g, 0.61 mmol), Al(CH₃)₃ in heptane 2.0 M (0.31 mL, 0.61 mmol) in THF (10 mL) were heated at 125 °C for 35 min in a microwave reactor. The crude was purified: Biotage KP-Sil 25g, EtOAc/Hexane from (5:95) up to (10:90) yielding a white solid (0.07 g, 45 %). M.p. 140 °C. ¹H NMR (300 MHz, DMSO-*d*₆) δ (ppm) 10.46 (s, 1H, NH), 8.35 (t, *J* = 5.6 Hz, 1H, CH₂NH), 7.91 (m, 1H, H-Ar), 7.86 (bs, 5H-Ar), 7.58 – 7.51 (m, 2H, H-Ar), 7.32 – 7.17 (m, 5H, H-Ar), 4.69 (m, 1H), 4.42 (m, 1H), 4.23 (m, 1H), 4.06 (m, 1H), 4.00 – 3.89 (m, 1H), 3.25 (m, 2H, NHCH₂), 3.06 (dd, *J*_{ab} = 13.6, *J*_{a4} = 4.2 Hz, 1H), 2.77 (dd, *J*_{ba} = 13.6, *J*_{b4} = 8.1 Hz, 1H), 1.52 (m, 2H), 1.42 – 1.18 (m, 4H), 0.85 (t, *J* = 6.8 Hz, 3H, CH₃). ¹³C NMR (75 MHz, DMSO-*d*₆) δ (ppm) 166.0 (CO), 165.9 (CO), 158.1, 141.9, 137.6, 136.5, 135.5, 131.4, 130.1, 129.6 (2C), 129.1, 128.9 (2C), 128.2 (2C), 127.6, 127.2, 127.1, 119.8 (2C), 66.7 (C), 55.7 (C), 45.5 (C), 40.7 (CH₂), 37.6 (C), 29.2 (CH₂), 29.1 (CH₂), 22.3 (CH₂), 14.3 (CH₃). HPLC/MS: gradient elution (40 to 95 % over 10.0 min) of acetonitrile in water, retention

time 5.09 min $[M+H]^+ = 500$. Elemental analysis calcd. for $C_{30}H_{33}N_3O_4$: C, 72.12; H, 6.66; N, 8.41; found C, 72.40; H, 6.83; N, 8.68.

(R)-3-[(4-benzyl-2-oxooxazolidin-3-yl)methyl]-N-[4-(dodecylcarbamoyl)phenyl]benzamide (5). Compound **18** (0.06 g, 0.18 mmol), compound **17e** (0.11 g, 0.36 mmol), $Al(CH_3)_3$ in heptane 2.0 M (0.18 mL, 0.36 mmol) in THF (10 mL) were heated at 125 °C for 35 min in a microwave reactor. The organic layers were dried and the solvent was evaporated under reduced pressure and the crude was purified: Biotage KP-Sil 25g, EtOAc/Hexane from (5:95) up to (10:90) yielding a white solid (0.05 g, 45 %). M.p. 115 °C. 1H NMR (300 MHz, $CDCl_3$) δ (ppm) 8.69 – 8.56 (m, 1H, NH), 7.94 – 7.64 (m, 5H, H-Ar), 7.53 – 7.19 (m, 4H, H-Ar), 7.13 – 7.00 (m, 3H, H-Ar), 6.34 – 6.14 (m, 1H, H-Ar), 4.81 (m, 1H), 4.30 – 4.13 (m, 1H), 4.02 (m, 1H), 3.94 – 3.79 (m, 1H), 3.45 – 3.30 (m, 1H), 3.06 (dd, $J_{ab} = 13.6$, $J_{a4} = 4.8$ Hz, 1H), 2.66 (dd, $J_{ba} = 13.6$, $J_{b4} = 8.6$ Hz, 1H), 1.60 – 1.55 (m, 2H, CH_2), 1.46 – 1.15 (m, 18H, 9 CH_2), 0.87 (t, $J = 6.7$ Hz, 3H, CH_3). ^{13}C NMR (75 MHz, $CDCl_3$) δ (ppm) 166.9 (CO), 165.6 (CO), 158.6 (C), 140.7, 139.7, 136.7, 135.4, 135.3, 131.4, 130.5, 129.3, 129.0 (2C), 127.8 (2C), 127.3, 127.0, 126.6, 119.9 (2C), 116.7, 67.2 (C), 55.7 (C), 46.1 (C), 40.2 (CH_2), 38.7 (C), 31.9 (CH_2), 29.6 (4 CH_2), 29.3 (3 CH_2), 27.0 (CH_2), 22.7 (CH_2), 14.1 (CH_3). HPLC/MS: gradient elution (40 to 95 % over 10.0 min) of acetonitrile in water, retention time 9.93 min $[M+H]^+ = 599$. Elemental analysis calcd. for $C_{37}H_{47}N_3O_4$: C, 74.34; H, 7.93; N, 7.03; found C, 74.20; H, 7.50; N, 7.04.

(R)-3-[(4-benzyl-2-oxooxazolidin-3-yl)methyl]-N-[4-((cyclopropyl)carbamoyl)phenyl]benzamide (6). Compound **18** (0.18 g, 0.56 mmol), compound **17f** (0.18 g, 0.67 mmol), $Al(CH_3)_3$ in heptane 2.0 M (1.11 mL, 2.24 mmol) in THF (10 mL) were heated at 125 °C for 35 min in a microwave reactor. The residue was purified:

Biotage KP-Sil 25g, EtOAc/Hexane (4:6) yielding a white solid (0.05 g, 2 %). ^1H NMR (300 MHz, MeOD) δ (ppm) 7.90 – 7.88 (m, 1H), 7.84 (bs, 2H), 7.79 – 7.77 (m, 2H), 7.55 – 7.51 (m, 4H), 7.30 – 7.26 (m, 2H), 7.18 – 7.16 (m, 2H), 4.81 (d, J = 4.8 Hz, 1H), 4.36 (d, J = 4.4 Hz, 1H), 4.30 – 4.26 (m, 1H), 4.15 – 4.12 (m, 1H), 4.06 – 4.02 (m, 1H), 3.11 (dd, J = 13.7, 5.1 Hz, 1H), 2.87 – 2.80 (m, 2H), 0.83 – 0.79 (m, 2H), 0.66 – 0.63 (m, 2H). ^{13}C NMR (75 MHz, MeOD) δ 169.7 (C), 167.2 (C), 159.5 (C), 141.7 (C), 137 (C), 135.9 (C), 135.3 (C), 131.1 (2CH), 129.5 (C), 128.9 (2CH), 128.8 (2CH), 128.4 (2CH), 126.9 (2CH), 126.7 (CH), 119.8 (2CH), 67.2 (CH₂), 55.9 (CH), 45.5 (CH₂), 37.8 (CH₂), 22.6 (CH), 5.14 (2CH₂).

(*R*)-3-[(4-benzyl-2-oxooxazolidin-3-yl)methyl]-*N*-[4-((cyclohexylmethyl)carbamoyl)phenyl]benzamide (7). Compound **18** (0.06 g, 0.18 mmol), compound **17g** (0.08 g, 0.36 mmol), $\text{Al}(\text{CH}_3)_3$ in heptane 2.0 M (0.18 mL, 0.36 mmol) in THF (10 mL) were heated at 125 °C for 35 min in a microwave reactor. The residue was purified: Biotage KP-Sil 25g, EtOAc/Hexane from (5:95) up to (10:90) yielding a white solid (0.04 g, 42 %). M.p. 130 °C. ^1H NMR (300 MHz, CDCl_3) δ (ppm) 9.08 (s, 1H, NH), 7.85 (m, 1H, H-Ar), 7.78 – 7.61 (m, 5H, H-Ar), 7.45 – 7.16 (m, 5H, H-Ar), 7.09 – 6.96 (m, 2H, H-Ar), 6.50 (t, J = 6.0 Hz, 1H, CH_2NH), 4.73 (m, 1H), 4.21 – 4.06 (m, 2H), 4.00 (m, 1H), 3.93 – 3.79 (m, 1H), 3.25 (m, 2H, CH_2NH), 3.03 (dd, J_{ab} = 13.6, J_{a4} = 4.9 Hz, 1H), 2.63 (dd, J_{ba} = 13.6, J_{b4} = 8.6 Hz, 1H), 1.82 – 1.52 (m, 6H), 1.32 – 1.10 (m, 4H), 0.93 (m, 1H). ^{13}C NMR (75 MHz, CDCl_3) δ (ppm) 166.9 (CO), 165.5 (CO), 158.5 (C), 140.8, 136.8, 135.4, 135.3, 131.4, 130.5, 129.3, 129.0, 127.9 (3C), 127.3 (2C), 127.0, 126.6, 119.8, 119.7 (2C), 67.2 (C), 55.7 (C), 46.3 (CH_2NH), 46.1, 38.8 (C), 38.0 (CH), 30.9 (2CH₂), 26.4 (CH₂), 25.8 (2CH₂). HPLC/MS: gradient elution (40 to 95 % over 10.0 min) of acetonitrile in water, retention time 5.71 min $[\text{M}+\text{H}]^+ = 527$. Elemental analysis calcd. for $\text{C}_{32}\text{H}_{35}\text{N}_3\text{O}_4$: C, 73.12; H, 6.71; N, 7.99; found C, 73.44; H, 6.58; N, 7.52.

(S)-3-[(4-benzyl-2-oxooxazolidin-3-yl)methyl]-N-[4-((4-*tert*-butyl)benzyl)carbamoyl]phenyl]benzamide (8). Compound **19** (0.20 g, 0.62 mmol), compound **17b** (0.21 g, 0.74 mmol), $\text{Al}(\text{CH}_3)_3$ in heptane 2.0 M (1.24 mL, 2.48 mmol) in THF (10 mL) were heated at 125 °C for 20 min in a microwave reactor. The residue was purified: Biotage KP-Sil 25g, EtOAc/Hexane (8:2) yielding a white solid (0.02 g, 4 %). M.p. 171 °C. ^1H NMR (300 MHz, CDCl_3) δ (ppm) 8.32 (s, 1H, H), 7.89 – 7.71 (m, 6H), 7.48 – 7.22 (m, 9H, H), 7.06 (d, J = 7.53 Hz, 2H), 6.44 (s, 1H), 4.81 (d, J = 15.28 Hz, 1H), 4.61 (s, 2H), 4.23 – 4.15 (m, 2H, H), 4.04 (dd, J = 5.78, 8.91 Hz, 1H), 3.89 (m, 1H), 3.08 (dd, J = 4.69, 13.47 Hz, 1H), 2.68 (dd, J = 8.42, 13.47 Hz, 1H), 2.17 (s, 9H). ^{13}C NMR (MHz, CDCl_3) δ 166.7, 165.4, 158.5, 150.7, 140.9, 136.8, 135.3, 135.0, 131.5, 129.4, 129.0, 128.1, 127.8, 127.3, 127.0, 126.6, 125.7, 119.8, 67.2, 55.7, 46.1, 43.9, 38.8, 34.5, 31.3. HPLC/MS: gradient elution 30-95% in 10 min, retention time=7.66, m/z $[\text{M}+\text{H}]^+ = 576$. Elemental analysis calcd. for $\text{C}_{36}\text{H}_{37}\text{N}_3\text{O}_4$: C, 75.11; H, 6.48; N, 7.30; found C, 75.10; H, 6.29; N, 7.18.

(S)-3-[(4-benzyl-2-oxooxazolidin-3-yl)methyl]-N-[4-((4-(trifluoromethyl)benzyl)carbamoyl)phenyl]benzamide (9). Compound **19** (0.20 g, 0.62 mmol), compound **17c** (0.22 g, 0.74 mmol), $\text{Al}(\text{CH}_3)_3$ in heptane 2.0 M (1.24 mL, 2.48 mmol) in THF (10 mL) were heated at 125 °C for 35 min in a microwave reactor. The residue was purified: Biotage KP-Sil 25g, EtOAc/Hexane from (5:95) up to (10:90) yielding a white solid (0.32 g, 87 %). M.p. 176 °C. ^1H NMR (300 MHz, MeOD) δ (ppm) 7.93-7.78 (m, 4H), 7.65-7.50 (m, 7H), 7.27-7.15 (m, 6H), 4.75 (d, J = 15.32 Hz, 1H), 4.61 (d, J = 5.84 Hz, 2H), 4.57-4.50 (m, 1H), 4.48-4.32 (m, 1H), 4.26-4.15 (m, 1H), 4.10-4.02 (m, 1H), 3.08 (dd, J = 4.88, 13.53 Hz, 1H), 2.81 (dd, J = 7.78, 13.35 Hz, 1H). ^{13}C NMR (75 MHz, MeOD) δ (ppm) 169.6 (CO), 168.6 (CO), 160.9, 145.0, 143.3, 138.4, 137.3, 136.6, 133.7, 132.5, 130.8, 130.3, 130.2, 129.8, 129.2, 127.1

(c, J = 30.31 Hz), 126.8, 126.4 (c, J = 9.17 Hz), 126.1 (d, J = 214.1 Hz), 124.7, 121.3, 68.6, 57.3, 46.8, 44.0, 39.2. HPLC/MS: gradient elution (30 to 95 % over 10 min), retention time 6.84 min $[M+H]^+ = 588$.

(*S*)-3-[(4-benzyl-2-oxooxazolidin-3-yl)methyl]-*N*-[4-(pentylcarbamoyl)phenyl]benzamide (10). Compound **19** (0.20 g, 0.62 mmol), compound **17d** (0.15 g, 0.74 mmol), $Al(CH_3)_3$ in heptane 2.0 M (1.24 mL, 2.48 mmol) in THF (10 mL) were heated at 125 °C for 10 min in a microwave reactor. The crude was purified: Biotage KP-Sil 25g, EtOAc/Hexane from (5:95) up to (10:90) yielding a white solid (0.25 g, 80 %). M.p. 267 °C. 1H NMR (300 MHz, DMSO- d_6) δ (ppm) 8.36 (bs, 1H, NH), 7.92-7.82 (m, 3H), 7.57-7.53 (m, 4H), 7.31-7.19 (m, 6H), 4.69 (d, J = 15.61 Hz, 1H), 4.42 (d, J = 15.54 Hz, 1H), 4.26-4.20 (m, 1H), 4.08-4.03 (m, 1H), 3.98-3.89 (m, 1H), 3.36-3.32 (m, 2H), 3.05 (dd, J = 3.78, 13.32 Hz, 1H), 2.75 (dd, J = 8.12, 13.43 Hz, 1H), 1.56-1.47 (m, 2H), 1.32-1.26 (m, 4H), 0.87 (t, J = 6.46 Hz, 3H). ^{13}C NMR (75 MHz, DMSO- d_6) δ (ppm) 165.6 (CO), 165.5 (CO), 157.7, 141.5, 137.3, 136.1, 135.1, 131.0, 129.7, 129.3, 128.7, 128.5, 127.8, 126.8, 126.7, 119.5, 66.3, 55.3, 45.1, 38.7, 37.2, 28.9, 28.7, 21.9, 13.9. HPLC/MS: gradient elution (30 to 95 % over 10 min), retention time 6.30 min $[M+H]^+ = 500$.

***N*-[3-((*S*)-3-((*R*)-4-benzyl-2-oxooxazolidin-3-yl)-2-methyl-3-oxopropyl)phenyl)-4-(2-(4-(*tert*-butyl)phenyl)acetamido]benzamide (11).**

To a solution of **23** (0.16 g, 0.56 mmol) in dry THF was added **21a** in dry THF (10 mL) under nitrogen atmosphere and stirred for 12 h. The reaction mixture was treated with 1 N HCl aqueous solution (10 mL) and extracted with AcOEt (20 mL). The organic layer was washed with saturated aqueous NH_4Cl and dried over $MgSO_4$. The residue was purified: Biotage KP-Sil 25g, EtOAc/Hexane from (5:95) up to (10:90) yielding a white solid (0.24 g, 68 %). M.p. 130 °C. $[\alpha]_D^{20} = -16.9$. 1H NMR (300 MHz, $CDCl_3$) δ (ppm) 7.75 (m, 2H, H-Ar), 7.68 – 7.60 (m, 1H, H-

Ar), 7.54 (m, 2H, H-Ar), 7.44 (m, 3H, H-Ar), 7.32 – 7.20 (m, 6H, H-Ar), 7.13 – 7.00 (m, 3H, H-Ar), 4.66 (m, 1H, CH), 4.23 – 4.00 (m, 3H, CH₂/CH), 3.74 (s, 2H, CH₂CO), 3.25 – 3.06 (m, 2H), 2.63 (m, 2H), 1.34 (s, 9H, 3CH₃), 1.18 (d, $J = 6.6$ Hz, 3H, CH₃). ¹³C NMR (75 MHz, CDCl₃) δ (ppm) 176.4 (CO), 176.3 (CO), 169.5 (CO), 153.1 (C-2), 150.9, 140.8, 140.2, 138.0, 135.1, 130.8, 129.4 (2C), 129.2 (2C), 129.1, 128.9 (2C), 128.1 (2C), 127.3, 126.3 (2C), 125.5, 120.8, 119.3 (2C), 118.4, 66.0 (C), 55.2 (C), 44.5 (CH₂), 39.7 (C), 39.6 (C), 37.8 (C), 34.6 (C(CH₃)), 31.3 (3CH₃), 16.5 (CH₃). HPLC/MS: retention time 8.78 min [M+H]⁺ = 632. Elemental analysis calcd. for C₃₉H₄₁N₃O₅: C, 74.14; H, 6.54; N, 6.65; found C, 73.89; H, 6.82; N, 6.41.

***N*-[3-((*S*)-3-((*R*)-4-benzyl-2-oxooxazolidin-3-yl)-2-methyl-3-oxopropyl)phenyl]-4-hexanamidobenzamide (12).** To a solution of **23** (0.39 g, 1.65 mmol) in dry THF was added **21b** in dry THF (10 mL) under nitrogen atmosphere and stirred for 12 h. The reaction mixture was treated with 1 N HCl aqueous solution (10 mL) and extracted with AcOEt (20 mL). The organic layer was washed with saturated aqueous NH₄Cl and dried over MgSO₄. The residue was purified: Biotage KP-Sil 25g, EtOAc/Hexane from (5:95) up to (10:90) yielding a white solid (0.21 g, 34 %). M.p. 141 °C. [α]_D²⁰ = -32.2. ¹H NMR (300 MHz, CDCl₃) δ (ppm) 8.13 – 8.10 (bs, 1H, NH), 7.86 – 7.81 (bs, 1H, NH), 7.76 – 7.70 (m, 2H, H-Ar), 7.67 – 7.54 (m, 3H, H-Ar), 7.47 – 7.37 (m, 2H, H-Ar), 7.24 – 7.15 (m, 4H, H-Ar), 7.11 – 7.00 (m, 2H, H-Ar), 4.67 – 4.57 (m, 1H), 4.22 – 4.01 (m, 3H), 3.14 – 3.06 (m, 2H), 2.62 – 2.50 (m, 2H), 2.36 (t, $J = 7.6$ Hz, 2H, CH₂CO), 1.70 – 1.59 (m, 2H), 1.37 – 1.23 (m, 4H), 1.16 (d, $J = 6.7$ Hz, 3H, CH₃CH), 0.97 – 0.79 (t, $J = 6.6$ Hz, 3H, CH₃). ¹³C NMR (75 MHz, CDCl₃) δ (ppm) 176.3 (CO), 172.1 (CO), 165.3 (CO), 153.2, 141.3, 140.1, 138.1, 135.1, 129.9, 129.3 (2C), 129.0, 128.9 (2C), 128.2 (2C), 127.3 (2C), 125.5, 121.0, 119.3, 118.6, 66.0, 55.2, 39.7, 39.6, 37.8, 37.7 (CH₂CO), 31.4 (CH₂), 25.2 (CH₂), 22.4 (CH₂), 16.5 (CH₃CH), 13.9 (CH₃). HPLC/MS: retention time 7.70 min [M+H]⁺ =

556. Elemental analysis calcd. for $C_{33}H_{37}N_3O_5$: C, 71.33; H, 6.71; N, 7.56; found C, 71.18 ; H, 6.42 ; N, 7.31.

(S)-3-[3-(4-(2-(4-(*tert*-butyl)phenyl)acetamido)benzamido)phenyl]-2-methylpropanoic acid (13).

To a solution of **11** (0.14 g, 0.22 mmol) in THF/H₂O (3:1) (30 mL) at 0 °C were added 30 % H₂O₂ aqueous solution (0.1 mL, 0.88 mmol) and LiOH (0.01 g, 0.44 mmol) in H₂O (2 mL). The solution was stirred for 2 h at r.t. The reaction mixture was treated with 1 N HCl aqueous solution (1 mL) and extracted with AcOEt (2x 20 mL). The organic layers were washed with brine and dried over MgSO₄. The residue was purified: Biotage KP-Sil 25g, Ethanol/CH₂Cl₂ (0-6 %) yielding a white solid (0.07 g, 70 %). M.p 180.9 °C. $[\alpha]_D^{20} = 11.1$. ¹H NMR (300 MHz, DMSO-*d*₆) δ (ppm) 12.16 (s, 1H, COOH), 10.40 (s, 1H, NH), 10.04 (s, 1H, NH), 7.92 (d, *J* = 8.7 Hz, 2H), 7.72 (d, *J* = 8.7 Hz, 2H), 7.64 – 7.57 (m, 2H, H-Ar), 7.34 (m, 2H, H-Ar), 7.26 (m, 3H, H-Ar), 6.91 (m, 1H, H-Ar), 3.62 (s, 2H, CH₂CO), 2.89 (m, 1H), 2.66 – 2.54 (m, 2H), 1.26 (s, 9H, 3CH₃), 1.05 (d, *J* = 6.5 Hz, 3H, CH₃). ¹³C NMR (75 MHz, DMSO-*d*₆) δ (ppm) 176.7 (CO), 169.7 (CO), 164.7 (CO), 148.9 , 142.1, 139.9, 139.1, 132.6, 130.3, 129.1, 128.8 (2C), 128.5 (2C), 128.3, 125.1 (2C), 123.9, 120.8, 118.2 (2C) , 42.9 (CH₂CO), 40.6, 38.7, 34.1 (C(CH₃)₃), 31.1 (3CH₃), 16.7 (CH₃). HPLC/MS: gradient elution (40 to 95 % over 10.0 min) of acetonitrile in water, retention time 6.72 min $[M+H]^+ = 473$. Elemental analysis calcd for C₂₉H₃₂N₂O₄: C, 73.7; H, 6.83; N, 5.93; found C, 74.00; H, 7.00; N, 5.70.

(S)-3-[3-(4-hexanamidobenzamido)phenyl]-2-methylpropanoic acid (14). To a solution of **12** (0.10 g, 0.18 mmol) in THF/H₂O (3:1) (30 mL) at 0 °C were added 30 % H₂O₂ aqueous solution (0.1 mL, 0.72 mmol) and LiOH (0.008 g, 0.36 mmol) in H₂O (2 mL). The solution was stirred for 2 h at r.t. The reaction mixture was treated with 1 N HCl aqueous solution (1 mL) and

was extracted with AcOEt (2x 20 mL). The organic layers were washed with brine and dried over MgSO₄. The residue was purified: Biotage KP-Sil 25g, CH₃OH/CH₂Cl₂ (0-6 %) yielding a white solid (0.09 g, 62 %). M.p 200 °C. $[\alpha]_D^{20} = 12.9$. ¹H NMR (300 MHz, DMSO-*d*₆) δ (ppm) 12.18 (s, 1H, COOH), 10.13 (s, 1H, NHCO), 10.03 (s, 1H, NHCO), 7.91 (d, *J* = 8.7 Hz, 2H), 7.71 (d, *J* = 8.5 Hz, 2H), 7.68 – 7.53 (m, 2H), 7.23 (m, 1H), 6.91 (m, 1H), 2.90 (m, 1H), 2.61 (m, 3H), 2.33 (t, *J* = 7.4 Hz, 2H, CH₂CO), 1.58 (m, 2H, CH₂), 1.28 (m, 4H, 2CH₂), 1.05 (d, *J* = 6.2 Hz, 3H, CH₃CH), 0.87 (t, *J* = 6.6 Hz, 3H, CH₃). ¹³C NMR (75 MHz, DMSO-*d*₆) δ (ppm) 176.7 (CO), 171.7 (CO), 164.7 (CO), 142.2, 139.9, 139.1, 128.7, 128.5 (2C), 128.2, 124.0, 120.7, 118.2, 118.1 (2C), 40.6 (CH), 38.6, 36.4 (CH₂CO), 30.9 (CH₂), 24.6 (CH₂), 21.9 (CH₂), 16.7 (CH₃CH), 13.8 (CH₃). HPLC/MS: retention time 7.93 min $[M+H]^+ = 236$. Elemental analysis calcd. for C₂₃H₂₈N₂O₄: C, 69.68; H, 7.12; N, 7.07; found C, 70.21; H, 7.08; N, 6.95.

4-[(*tert*-butoxycarbonyl)amino]benzoic acid (15). To a solution of 4-aminobenzoic acid (0.2 g, 1.5 mmol) in water/dioxane (1:2, 6 mL) were added Et₃N (0.4 mL, 3.0 mmol) and di-*tert*-butyl dicarbonate (0.6 g, 3.0 mmol). It was stirred at room temperature for 24 h. The solvent was evaporated and the residue was acidified with 1 N HCl aqueous solution. The obtained precipitate washed with water yielding **15** as white solid (0.47 g, 89 %). M.p. 181 °C. ¹H NMR (300 MHz, DMSO-*d*₆) δ (ppm) 12.21 (s, 1H, COOH), 9.71 (s, 1H, NH), 7.82 (d, *J* = 8.7 Hz, 2H), 7.54 (d, *J* = 8.7 Hz, 2H), 1.44 (s, 9H, 3CH₃). ¹³C NMR (75 MHz, DMSO-*d*₆) δ 167.4 (CO₂H), 152.9 (CONH), 144.1, 130.3 (C), 124.4, 117.6 (C), 80.0 (C(CH₃)₃), 28.4 (3CH₃). HPLC-MS: retention time 4.25 min $[M+H]^+ = 237$. Elemental analysis calcd. for C₁₂H₁₅NO₄: C, 60.75; H, 6.37; N, 5.90; found C, 60.84; H, 6.09; N, 5.95.

General Procedure for the Synthesis of 16a-g. To a cooled mixture of **15** (1 Eq) in THF or DMF was added Et₃N (1.2 Eq), HOBT (1.2 Eq) and corresponding coupling reagents (1.2 Eq).

Then, corresponding amines were added and mixture was stirred for 12 h at r.t. The reaction mixture was treated with 1 N HCl aqueous solution and extracted with AcOEt. The organic layers were washed with brine, dried over MgSO₄ and concentrated in vacuo. The residue was purified by flash chromatography.

4-[*N*-(*tert*-butoxycarbamoyl)amino]benzylamine (16a). To solution of **15** (0.20 g, 0.84 mmol) in THF at 0 °C were added PyBOP (0.53 g, 1.01 mmol), HOBt (0.14 g, 1.01 mmol), Et₃N (0.14 mL, 1.01 mmol) and benzylamine (0.11 mL, 1.01 mmol). The residue was purified: Biotage KP-Sil 25g, EtOAc/Hexane from (5:95) up to (10:90) yielding a white solid (0.19 g, 80 %). M.p. 150 °C. ¹H NMR (300 MHz, DMSO-*d*₆) δ 9.60 (s, 1H, NH), 8.86 (t, *J* = 6.0 Hz, 1H, NHCH₂), 7.80 (d, *J* = 8.7 Hz, 2H), 7.52 (d, *J* = 8.7 Hz, 2H), 7.38 – 7.18 (m, 5H), 4.45 (d, *J* = 5.9 Hz, 2H, NHCH₂), 1.47 (s, 9H, 3CH₃). ¹³C NMR (75 MHz, DMSO-*d*₆) δ 165.7 (CO), 152.5 (CO), 142.3, 139.8, 128.2 (C), 128.0 (C), 127.6, 127.1, 126.1, 117.1, 79.4 (C(CH₃)₃), 42.5 (NHCH₂), 28.0 (3CH₃). HPLC-MS: retention time 9.05 min [M+H]⁺ = 327. Elemental analysis calcd. for C₁₉H₂₂N₂O₃: C, 69.92; H, 6.79; N, 8.58; found C, 70.16; H, 6.49; N, 8.58.

4-[*N*-(*tert*-butoxycarbamoyl)amino]-*N*-(*tert*-butyl)benzylamine (16b). To solution of **15** (0.30 g, 1.26 mmol) in THF (20 mL) at 0 °C were added PyBOP (0.79 g, 1.52 mmol), HOBt (0.21 g, 1.52 mmol), Et₃N (0.21 mL, 1.52 mmol) and 4-(*tert*-butyl)-benzylamine (0.08 g, 1.52 mmol). The residue was purified: Biotage KP-Sil 25g, EtOAc/Hexane from (5:95) up to (10:90) yielding a white solid (0.3 g, 60 %). M.p. 112 °C. ¹H NMR (300 MHz, CDCl₃) δ (ppm) 7.72 (d, *J* = 8.6 Hz, 2H), 7.42 (d, *J* = 8.4 Hz, 2H), 7.38 (d, *J* = 8.4 Hz, 2H), 7.29 (d, *J* = 8.6 Hz, 2H) 6.77 (s, 1H, NH), 6.37 (t, *J* = 5.7 Hz, 1H, NHCH₂), 4.59 (d, *J* = 5.4 Hz, 2H, NHCH₂), 1.51 (s, 9H, 3CH₃), 1.31 (s, 9H, 3CH₃). ¹³C NMR (75 MHz, CDCl₃) δ (ppm) 166.7 (CO), 152.3 (CO), 150.6, 141.5, 135.2, 128.5, 128.0 (C), 127.8 (C), 125.7 (C), 117.7 (C), 81.0 (OC(CH₃)₃), 43.8 (CH₂), 34.5

($\text{C}(\text{CH}_3)_3$), 31.3 (3CH₃), 28.3 (3CH₃). HPLC-MS: gradient elution (15 to 95 % over 5 min) of acetonitrile in water, retention time 5.71 min $[\text{M}+\text{H}]^+ = 383$. Elemental analysis calcd. for $\text{C}_{23}\text{H}_{30}\text{N}_2\text{O}_3$; C, 72.22; H, 7.91; N, 7.32; found C, 72.51; H, 7.95; N, 7.20.

4-[*N*-(*tert*-butoxycarbonyl)amino]-*N*-(4-trifluoromethyl)benzylamine (16c). To solution of **15** (0.10 g, 0.42 mmol) in THF (20 mL) at 0 °C were added PyBOP (0.26 g, 0.51 mmol), HOBT (0.07 g, 0.51 mmol), Et₃N (0.07 mL, 0.51 mmol) and 4-(trifluoromethyl)-benzylamine (0.07 mL, 0.51 mmol). The residue was purified: Biotage KP-Sil 25g, AcOEt/Hexane from (5:95) up to (10:90) gave **16c** as white solid (0.14 g, 84 %). M.p. 141 °C. ¹H NMR (300 MHz, DMSO-*d*₆) δ (ppm) 9.61 (s, 1H, NH), 8.96 (t, *J* = 6.0 Hz, 1H, NHCH_2), 7.81 (d, *J* = 8.8 Hz, 2H, CH-Ar), 7.68 (d, *J* = 8.8 Hz, 2H, CH-Ar), 7.56 – 7.47 (m, 4H, CH-Ar), 4.52 (d, *J* = 5.8 Hz, 2H, NHCH_2), 1.47 (s, 9H, 3CH₃). ¹³C NMR (75 MHz, DMSO-*d*₆) δ (ppm) 165.8 (CO), 152.5 (CO), 144.7, 142.4, 128.0, 127.8 (C), 127.3 (C), 125.9 (C), 125.1 (c, *J* = 268 Hz, CF₃), 117.1 (C), 79.4 ($\text{OC}(\text{CH}_3)_3$), 42.2 (CH₂), 28.0 (3CH₃). HPLC-MS: retention time 5.24 min $[\text{M}+\text{H}]^+ = 395$. Elemental analysis calcd. for $\text{C}_{20}\text{H}_{21}\text{F}_3\text{N}_2\text{O}_3$: C, 60.91; H, 5.37; N, 7.10; found C, 61.10; H, 5.25; N, 6.88.

***tert*-butyl 4-(pentylcarbamoyl)phenylcarbamate (16d).** To solution of **15** (0.3 g, 1.26 mmol) in THF (20 mL) at 0 °C were added PyBOP (0.78 g, 1.52 mmol), HOBT (0.21 g, 1.52 mmol), Et₃N (0.21 mL, 1.52 mmol) and 1-pentylamine (0.17 mL, 1.52 mmol). The residue was purified: Biotage KP-Sil 25g, 2 % CH₃OH in CH₂Cl₂ yielding an orange solid (0.12 g, 33 %). M.p. 99 °C. ¹H NMR (300 MHz, CDCl₃) δ (ppm) 7.70 (d, *J* = 8.6 Hz, 2H), 7.42 (d, *J* = 8.6 Hz, 2H), 6.70 (bs, 1H, NHCH_2), 6.08 (s, 1H, NH), 3.41 – 3.38 (m, 2H, NHCH_2CH_2), 1.52 (s, 9H, 3CH₃), 1.40 – 1.29 (m, 6H, 3CH₂), 0.91 (t, *J* = 6.8 Hz, 3H, CH₃). ¹³C NMR (75 MHz, CDCl₃) δ (ppm) 166.8 (CO), 152.3 (CO), 141.2, 129.0, 127.9 (C), 117.7 (C), 81.0 ($\text{OC}(\text{CH}_3)_3$), 40.0 (CH₂),

29.4 (CH₂), 29.1 (CH₂), 28.2 (3CH₃), 22.4 (CH₂), 13.9 (CH₃). HPLC-MS: retention time 5.03 min [M+H]⁺ = 307. Elemental analysis calcd. for C₁₇H₂₆N₂O₃: C, 66.64; H, 8.55; N, 9.14; found C, 66.20; H, 8.30; N, 9.11.

***tert*-butyl (4-(dodecylcarbamoyl)phenyl)carbamate (16e).** To solution of **15** (0.20 g, 0.84 mmol) in THF (20 mL) at 0 °C were added PyBOP (0.19 g, 1.01 mmol), HOBt (0.19 g, 1.01 mmol), Et₃N (0.14 mL, 1.01 mmol) and 1-dodecylamine (0.23 mL, 1.01 mmol). The residue was purified: Biotage KP-Sil 25g, EtOAc/Hexane from (5:95) up to (10:90) yielding a white solid (0.22 g, 65 %). M.p. 110 °C. ¹H NMR (300 MHz, CDCl₃) δ (ppm) 7.69 (d, *J* = 8.6 Hz, 2H), 7.42 (d, *J* = 8.6 Hz, 2H), 6.70 (s, 1H, NHCO-O), 6.12 (bs, 1H, NHCH₂), 3.42 (m, 2H, CH₂NH), 1.61 (m, 2H, CH₂), 1.52 (s, 9H, 3CH₃), 1.42 – 1.17 (m, 18H, 9CH₂), 0.86 (t, *J* = 7.1, 3H, CH₃). ¹³C NMR (75 MHz, CDCl₃) δ (ppm) 166.8 (CO), 152.3 (CO), 141.3, 128.9, 127.9, 117.7, 81.0 (OC(CH₃)₃), 40.1 (CH₂N), 31.9 (CH₂), 29.7 (CH₂), 29.6 (CH₂), 29.54 (CH₂), 29.50 (CH₂), 29.3 (3CH₂), 28.3 (3CH₃), 27.0 (CH₂), 22.6 (CH₂), 14.1 (CH₃). HPLC-MS: retention time 6.0 min [M+H]⁺ = 405. Elemental analysis calcd. for C₂₄H₄₀N₂O₃: C, 71.25; H, 9.97; N, 6.92; found C, 71.08; H, 10.12; N, 6.63.

***tert*-butyl (4-((cyclopropyl)carbamoyl)phenyl)carbamate (16f).** To a solution of **15** (0.50 g, 2.11 mmol) in DMF (25 mL) at 0 °C were added EDCI (0.61 g, 3.17 mmol), HOBt (0.43 g, 3.17 mmol), Et₃N (0.88 mL, 6.33 mmol) and cyclopropylamine (0.22 mL, 3.17 mmol). The residue was purified: Biotage KP-Sil 25g, EtOAc/Hexane from (5:95) up to (10:90) yielding a white solid (0.28 g, 48 %). M.p. 184 °C. ¹H NMR (300 MHz, MeOD) δ (ppm) 7.72 (d, *J* = 8.8 Hz, 2H), 7.48 (d, *J* = 8.8 Hz, 2H), 2.82 (dq, *J* = 7.4, 3.9 Hz, 1H), 1.52 (s, 9H), 0.93 – 0.73 (m, 2H), 0.69 – 0.50 (m, 2H). ¹³C NMR (75 MHz, MeOD) δ 164.6 (CO), 155.2 (CO), 144.5 (C), 139.15 (C), 129.6 (2CH), 119.1 (2CH), 81.6 (C), 29.0 (3CH₃), 24.3 (CH), 6.95 (2CH₂). HPLC-MS:

retention time 7.84 min $[M+H]^+ = 277$. Elemental analysis calcd. for $C_{15}H_{20}N_2O_3$: C, 65.2; H, 7.3; N, 10.14; found C, 68.18; H, 6.94; N, 10.08.

***tert*-butyl (4-((cyclohexylmethyl)carbamoyl)phenyl)carbamate (16g).** To a solution of **15** (0.14 g, 0.57 mmol) in THF (20 mL) at 0 °C were added EDCI (0.17 g, 0.88 mmol), HOBT (0.12 g, 0.88 mmol), Et_3N (0.12 mL, 0.88 mmol) and cyclohexylamine (0.11 mL, 0.88 mmol). The residue was purified: Biotage KP-Sil 25g, EtOAc/Hexane from (5:95) up to (10:90) yielding a white solid (0.06 g, 31 %). M.p. 114 °C. 1H NMR (300 MHz, $DMSO-d_6$) δ (ppm) 9.56 (s, 1H, NH), 8.24 (t, $J = 5.8$ Hz, 1H, $NHCH_2$), 7.74 (d, $J = 8.7$ Hz, 2H), 7.49 (d, $J = 8.7$ Hz, 2H), 3.05 (m, 2H, $NHCH_2$), 1.67 (m, 5H), 1.47 (s, 9H, 3 CH_3), 1.24 – 1.01 (m, 4H), 0.90 (m, 2H). ^{13}C NMR (75 MHz, $DMSO-d_6$) δ (ppm) 165.7 (CO), 152.6 (CO), 142.0, 128.06, 127.9 (C), 117.0 (C), 79.4 ($OC(CH_3)_3$), 45.3 ($NHCH_2$), 37.5 (C), 30.5 (C), 28.0 (3 CH_3), 26.1 (C), 25.4 (C). HPLC-MS: retention time 6.02 min $[M+H]^+ = 333$. Elemental analysis calcd. for $C_{19}H_{28}N_2O_3$: C, 68.65; H, 8.49; N, 8.43; found C, 68.40; H, 8.70; N, 8.20.

General Procedure for the Synthesis of 17a-g. The corresponding *N*-Boc amino acid (**16a-g**) was treated with a mixture of TFA and dichloromethane (1:1, 40 mL) at room temperature for 12 h. The mixture reaction was quenched with aqueous 1 N NaOH (15 mL). The organic layer separated, washed with water and dried over anhydrous $MgSO_4$. The solvent was evaporated under reduced pressure obtaining the desired compounds.

4-amino-*N*-benzylbenzamide (17a). General method was used with compound **16a** (0.35 g, 1.07 mmol). White solid (0.22 g, 92 %). M.p. 150 °C. 1H NMR (300 MHz, $DMSO-d_6$) δ (ppm) 8.55 (t, $J = 6.1$ Hz, 1H, $NHCH_2$), 7.62 (d, $J = 8.6$ Hz, 2H), 7.40 – 7.17 (m, 5H, H-Ar), 6.54 (d, $J = 8.6$ Hz, 2H), 5.60 (bs, 2H, NH_2), 4.42 (d, $J = 5.9$ Hz, 2H, $NHCH_2$). ^{13}C NMR (75 MHz, $DMSO-d_6$) δ (ppm) 166.2 (CO), 151.6, 140.3, 128.7 (C), 128.1, 127.1, 126.5, 125.3, 124.2,

121.0, 112.5 (C), 42.3 (CH₂). HPLC-MS: retention time 8.5 min [M+H]⁺ = 227. Elemental analysis calcd. for C₁₄H₁₄N₂O: C, 74.31; H, 6.24; N, 12.38. found C, 74.39; H, 6.43; N, 12.55.

4-amino-*N*-(4-(*tert*-butyl)benzyl)benzamide (17b). General method was used with compound **16b** (0.20 g, 0.52 mol). White solid (0.13 g, 90 %). M.p. 113 °C. ¹H NMR (300 MHz, CDCl₃) δ (ppm) 7.62 (d, *J* = 8.3 Hz, 2H), 7.37 (d, *J* = 8.2 Hz, 2H), 7.29 (d, *J* = 8.2 Hz, 2H), 6.64 (d, *J* = 8.3 Hz, 2H), 4.59 (d, *J* = 5.4 Hz, 2H, NHCH₂), 1.32 (s, 9H, 3CH₃). ¹³C NMR (75 MHz, CDCl₃) δ (ppm) 167.0 (CO), 150.5, 149.5, 135.5, 128.7 (C), 127.7 (C), 125.6 (C), 124.0, 114.1 (C), 43.7 (CH₂), 34.5 (C(CH₃)₃), 31.3 (3CH₃). HPLC-MS: retention time 4.67 min [M+H]⁺ = 283. Elemental analysis calcd. for C₁₈H₂₂N₂O: C, 76.56; H, 7.85; N, 9.92. found C, 76.71; H, 8.10; N, 9.94.

4-amino-*N*-(4-(trifluoromethyl)benzyl)benzamide (17c). General method was used with compound **16c** (0.20 g, 0.51 mol). White solid (0.14 g, 92 %). M.p. 113 °C. ¹H NMR (300 MHz, CDCl₃) δ (ppm) 7.63 (d, *J* = 8.0 Hz, 2H), 7.58 (d, *J* = 7.8 Hz, 2H), 7.44 (d, *J* = 7.8 Hz, 2H), 6.65 (d, *J* = 8.0 Hz, 2H), 6.42 (bs, 1H, NHCH₂), 4.67 (d, *J* = 5.8 Hz, 2H, NHCH₂), 4.34 – 3.49 (bs, 2H, NH₂). ¹³C NMR (75 MHz, CDCl₃) δ (ppm) 167.2 (CO), 149.8, 142.8, 131.1, 128.8 (C), 127.9 (C), 125.7 (C), 125.6, 124.9 (c, *J* = 268 Hz, CF₃), 114.1 (C), 43.4 (CH₂). HPLC-MS: retention time 4.21 min [M+H]⁺ = 295. Elemental analysis calcd. for C₁₅H₁₃F₃N₂O: C, 61.22; H, 4.45; N, 9.52. found C, 61.23; H, 4.60; N, 9.60.

4-amino-*N*-pentylbenzamide (17d). General method was used with compound **16d** (0.76 g, 3.68 mmol). White solid (0.44 g, 85 %). M.p. 100 °C. ¹H NMR (300 MHz, CDCl₃) δ (ppm) 7.58 (d, *J* = 8.6 Hz, 2H), 6.64 (d, *J* = 8.6 Hz, 2H), 6.01 (bs, 1H, NHCH₂), 3.40 – 3.37 (m, 2H, NHCH₂CH₂), 1.57 – 1.51 (m, 2H, NHCH₂CH₂), 1.43 – 1.24 (m, 4H, 2CH₂), 0.99 – 0.79 (t, *J* = 6.8 Hz, 3H, CH₃). ¹³C NMR (75 MHz, CDCl₃) δ (ppm) 167.2 (CO), 149.4, 128.5 (C), 124.4,

114.1 (C), 40.0 (CH₂), 29.5 (CH₂), 29.1 (CH₂), 22.4 (CH₂), 14.0 (CH₃). HPLC-MS: retention time 3.7 min [M+H]⁺ = 207. Elemental analysis calcd. for C₁₂H₁₈N₂O: C, 69.87; H, 8.80; N, 13.58. found C, 69.23; H, 8.60; N, 13.60.

4-amino-*N*-dodecylbenzamide (17e). General method was used with compound **16e** (0.20 g, 0.49 mmol). White solid (0.14 g, 92 %). M.p. 112 °C. ¹H NMR (300 MHz, CDCl₃) δ (ppm) 7.59 (d, *J* = 8.6 Hz, 2H), 6.65 (d, *J* = 8.6 Hz, 2H), 6.05 – 5.91 (bs, 1H, NH, NHCH₂), 3.40 (m, 2H, NHCH₂), 1.65 – 1.50 (m, 2H, NHCH₂CH₂), 1.45 – 1.16 (m, 18H, 9CH₂), 0.87 (t, *J* = 7.1, 3H, CH₃). ¹³C NMR (75 MHz, CDCl₃) δ (ppm) 167.2 (CO), 149.3, 128.9, 127.8, 114.1, 39.9 (NHCH₂), 31.9 (CH₂), 29.8 (CH₂), 29.6 (3CH₂), 29.3 (3CH₂), 27.0 (CH₂), 22.7 (CH₂), 14.1 (CH₃). HPLC-MS: retention time 11.0 min [M+H]⁺ = 305. Elemental analysis calcd. for C₁₉H₃₂N₂O: C, 74.95; H, 10.59; N, 9.20; found C, 74.60; H, 10.55; N, 9.16.

4-amino-*N*-cyclopropylbenzamide (17f). General method was used with compound **16f** (0.55 g, 1.99 mmol). White solid (0.22 g, 63 %). M.p. 142 °C. ¹H NMR (300 MHz, MeOD) δ 7.57 (d, *J* = 8.7 Hz, 2H), 6.64 (d, *J* = 8.7 Hz, 2H), 4.86 (s, 4H), 2.85 – 2.71 (m, 1H), 0.83 – 0.70 (m, 2H), 0.65 – 0.53 (m, 2H). ¹³C NMR (75 MHz, MeOD) δ 172.1 (CO), 153.2 (C), 129.9 (C), 123.1 (2CH), 114.6 (2CH), 23.8 (CH), 6.6 (2CH₂). HPLC-MS: retention time 1.2 min [M+H]⁺ = 177. Elemental analysis calcd. for C₁₀H₁₂N₂O: C, 68.16; H, 6.86; N, 15.90; found C, 67.97; H, 6.80; N, 15.75.

4-amino-*N*-(cyclohexylmethyl)benzamide (17g). General method was used with compound **16g** (0.20 g, 0.60 mmol). White solid (0.11 g, 80 %). M.p. 150 °C. ¹H NMR (300 MHz, DMSO-*d*₆) δ 7.92 (t, *J* = 5.8 Hz, 1H, CH₂NH), 7.54 (d, *J* = 8.6 Hz, 2H), 6.50 (d, *J* = 8.6 Hz, 2H), 5.60 – 5.48 (m, 2H, NH₂), 3.08 – 2.92 (m, 2H, CH₂NH), 1.66 – 1.62 (m, 5H), 1.47 – 1.41 (m, 1H), 1.13 – 1.11 (m, 3H), 0.95 – 0.77 (m, 2H). ¹³C NMR (75 MHz, DMSO-*d*₆) δ (ppm) 165.7 (CO), 142.0,

128.1, 127.6 (C), 116.0 (C), 45.3 (NHCH₂), 37.5 (C), 30.5 (C), 26.1 (C), 25.4 (C). HPLC-MS: retention time 5.34 min [M+H]⁺ = 333. Elemental analysis calcd. for C₁₄H₂₀N₂O: C, 72.38; H, 8.68; N, 12.06; found C, 72.60; H, 8.55; N, 12.16.

(R)-methyl-3-[(4-benzyl-2-oxooxazolidin-3-yl)methyl]benzoate (18). To a solution of (R)- 4-benzyl-3-propionyl-2-oxazolidinone (1.2 g, 5.24 mmol) in anhydrous THF (13 mL) was added potassium *tert*-butoxide (0.6 g, 5.24 mmol) and stirred for 45 min under nitrogen atmosphere at room temperature. Then methyl 3-bromomethyl benzoate (1.0 g, 4.36 mmol) was added to the stirred solution. The reaction mixture was stirred for 6 h. A saturated solution of NH₄Cl (15 mL) was added and the reaction extracted with ethyl acetate (30 mL). The combined organic extracts were washed successively with H₂O (30 mL), brine (30 mL) and dried over Na₂SO₄. The solvent was evaporated and the crude purified: Biotage KP-Sil 25g, EtOAc/Hexane from (5:95) up to (10:90) yielding a white solid (0.43 g, 62 %). M.p. 62 °C. ¹H NMR (300 MHz, CDCl₃) δ (ppm) 8.06 – 7.95 (m, 1H, H-Ar), 7.90 – 7.88 (m, 1H, H-Ar), 7.54 – 7.40 (m, 2H, H-Ar), 7.36 – 7.22 (m, 3H, H-Ar), 7.12 – 7.02 (m, 2H, H-Ar), 4.86 (d, *J* = 15.4 Hz, 1H), 4.18 (m, 2H), 4.10 – 4.02 (m, 1H), 3.93 (s, 3H, CH₃), 3.89 – 3.77 (m, 1H), 3.09 (dd, *J*_{ab} = 13.6, *J*_{a4} = 4.7 Hz, 1H), 2.66 (dd, *J*_{ba} = 13.6, *J*_{b4} = 8.9 Hz, 1H). ¹³C NMR (75 MHz, CDCl₃) δ (ppm) 166.5 (CO), 157.9, 136.4, 135.4, 132.4, 130.8, 129.3, 129.1, 129.0, 128.9, 127.1, 67.0, 55.5, 51.9 (OCH₃), 45.9, 38.3. HPLC-MS: retention time 4.8 min [M+H]⁺ = 326. Elemental analysis calcd. for C₁₉H₁₉NO₄: C, 70.14; H, 5.89; N, 4.31; found C, 70.31; H, 5.67; N, 4.60.

(S)-methyl-3-[(4-benzyl-2-oxooxazolidin-3-yl)methyl]benzoate (19). To a solution of (S)- 4-benzyl-3-propionyl-2-oxazolidinone (0.5 g, 2.82 mmol) in anhydrous THF/CH₃CN (20 mL, 1:1) was added Cs₂CO₃ (2.76 g, 8.46 mmol) and stirred for 45 min under nitrogen atmosphere at room temperature. Then methyl 3-bromomethyl benzoate (1.3 g, 5.64 mmol) was added to the

1
2
3 stirred solution. The reaction mixture was stirred for 6 h. A saturated solution of NH_4Cl (25 mL)
4 was added and the reaction extracted with ethyl acetate (2x30 mL). The combined organic
5 extracts were washed successively with water (30 mL), brine (30 mL) and dried over Na_2SO_4 .
6
7 The solvent was evaporated and the crude was purified: Biotage KP-Sil 25g, EtOAc/Hexane
8 from (5:95) up to (10:90) yielding a white solid (0.60 g, 66 %). M.p. 61.1 °C. ^1H NMR (300
9 MHz, CDCl_3) δ (ppm) 8.00 (d, J = 6.5 Hz, 1H), 7.90 (s, 1H), 7.52 - 7.40 (m, 2H), 7.35 – 7.17 (m,
10 3H), 7.10 - 6.99 (m, 2H), 4.86 (d, J = 15.4 Hz, 1H), 4.24 – 4.10 (m, 2H), 4.08 – 3.98 (m, 1H),
11 3.93 (s, 3 H), 3.88 – 3.73 (m, 1H), 3.09 (dd, J = 13.6, 4.8 Hz, 1H), 2.66 (dd, J = 13.6, 8.9 Hz,
12 1H). ^{13}C NMR (MHz, CDCl_3) δ (ppm) 166.6, 158.3, 136.3, 135.3, 132.6, 130.7, 129.3, 129.1,
13 129.0, 128.9, 127.2, 67.0, 55.5, 52.2, 46.1, 38.6. HPLC-MS: retention time 9.06 min $[\text{M}+\text{H}]^+=$
14 326. Elemental analysis calcd. for $\text{C}_{19}\text{H}_{19}\text{NO}_4$: C, 70.14; H, 5.89; N, 4.31; found C, 70.42; H,
15 5.62; N, 4.13.

16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32 **4-[2-(4-(*tert*-butyl)phenyl)acetamido]benzoic acid (20a).** 4-aminobenzoic acid (0.20 g, 1.46
33 mmol), methyl *p-tert*-butylphenylacetate (0.45 mL, 2.19 mmol), $\text{Al}(\text{CH}_3)_3$ in heptane 2.0 M
34 (1.10 mL, 2.19 mmol) in THF (10 mL) were heated at 125 °C for 40 min in a microwave reactor.
35
36 The reaction mixture was poured into an erlenmeyer, cooled in an ice bath and 1 N HCl aqueous
37 solution was slowly added until the effervescence ended. The mixture was extracted with AcOEt
38 (2x20 mL) and the organic layer was washed with saturated aqueous NH_4Cl and dried over
39 MgSO_4 . The residue was purified: Biotage KP-Sil 25g, EtOH/ CH_2Cl_2 0-6 % yielding a white
40 solid (0.30 g, 65 %). M.p. 155 °C. ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ (ppm) 12.66 (s, 1H, CO_2H),
41 10.43 (s, 1H, NH), 7.86 (d, J = 8.8 Hz, 2H), 7.69 (d, J = 8.8 Hz, 2H), 7.33 (d, J = 8.4 Hz, 2H), 7.24
42 (d, J = 8.4 Hz, 2H), 3.61 (s, 2H, CH_2CO), 1.34 (s, 9H, 3 CH_3). ^{13}C NMR (75 MHz, $\text{DMSO}-d_6$) δ
43 (ppm) 169.8(CO), 166.8 (CO), 148.9, 143.2, 132.6, 130.3, 128.7, 125.1, 118.3, 49.2 (CH_2CO),
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

34.1 ($\underline{\text{C}}(\text{CH}_3)_3$), 31.1 (3CH_3). HPLC/MS: retention time 5.25 min $[\text{M}+\text{H}]^+ = 312$. Elemental Analysis calcd. for $\text{C}_{19}\text{H}_{21}\text{NO}_3$: C, 73.29; H, 6.80; N, 4.50; found C, 73.10; H, 6.78; N, 4.52.

4-hexanamidobenzoic acid (20b). 4-aminobenzoic acid (0.25 g, 1.81 mmol), ethyl hexanoate (0.6 g, 3.64 mmol), $\text{Al}(\text{CH}_3)_3$ in heptane 2.0 M (1.82 mL, 3.64 mmol) in THF (20 mL) were heated at 125 °C for 20 min in a microwave reactor. The reaction mixture was poured into an erlenmeyer, cooled in an ice bath and 1 N HCl aqueous solution was slowly added until the effervescence ended. The precipitate obtained was washed with H_2O (2x10 mL) yielding a white solid (0.30 g, 70 %). M.p. 245 °C. ^1H NMR (300 MHz, $\text{DMSO}-d_6$) δ (ppm) 12.65 (s, 1H, CO_2H), 10.15 (s, 1H, NH), 7.86 (d, $J = 8.7$ Hz, 2H), 7.69 (d, $J = 8.7$ Hz, 2H), 2.32 (t, $J = 7.4$ Hz, 2H, $\underline{\text{CH}_2\text{CO}}$), 1.65 – 1.46 (m, 2H, CH_2), 1.40 – 1.18 (m, 4H, 2CH_2), 0.95 – 0.75 (t, $J = 6.7$ Hz, 3H, CH_3). ^{13}C NMR (75 MHz, $\text{DMSO}-d_6$) δ (ppm) 171.8 (CO), 166.9 (CO), 143.3, 130.3, 124.7, 118.2, 36.4 ($\underline{\text{CH}_2\text{CO}}$), 30.8 (CH_2), 24.6 (CH_2), 21.9 (CH_2), 13.8 (CH_3). HPLC/MS: retention time 7.93 min $[\text{M}+\text{H}]^+ = 236$. Elemental Analysis calcd. for $\text{C}_{13}\text{H}_{17}\text{NO}_3$: C, 66.36; H, 7.28; N, 5.95; found C, 66.50; H, 7.50; N, 5.84.

4-[2-(4-(*tert*-butyl)phenyl)acetamido]benzoyl chloride (21a). To a solution of **20a** (0.10 g, 0.32 mmol) in dry THF was added thionyl chloride (2 mL). The solution was stirred under reflux for 2 h. the solvent was removed under reduced pressure yielding (0.11 g).

4-hexanamidobenzoyl chloride (21b). To a solution of **20b** (0.10 g, 0.43 mmol) in dry THF was added thionyl chloride (2 mL). The solution was stirred under reflux for 2 h. the solvent was removed under reduced pressure yielding (0.11 g).

(*R*)-4-benzyl-3-[(*S*)-2-methyl-3-(3-nitrophenyl)propanoyl]oxazolidin-2-one (22). A solution of (*R*)-(-)-4-benzyl-3-propionyl-2-oxazolidinone (0.60 g, 2.58 mmol) in anhydrous THF (11 mL) was stirred for 15 min under nitrogen atmosphere at -78 °C. Then sodium bis(-

trimethylsilyl)amide 1.0 M in THF (2.84 mL, 2.84 mmol) was added dropwise with a syringe to the stirred solution. The reaction mixture was allowed to stir for 1 h at -78 °C. 1-bromomethyl-3-nitrobenzene (0.61 g, 2.84 mmol) was added and the reaction stirred at this temperature for 6 h. After reaching room temperature a saturated solution of NH₄Cl (15 mL) was added and the reaction extracted with ethyl acetate (30 mL). The combined organic extracts were washed successively with water (30 mL), brine (30 mL), and dried over Na₂SO₄. The residue was purified: Biotage KP-Sil 25g, EtOAc/Hexane from (5:95) up to (10:90) yielding an oil (0.67 g, 70 %). $[\alpha]_D^{20} = -56.0$. ¹H NMR (300 MHz, CDCl₃) δ (ppm) 8.22 – 8.04 (m, 2H, H-Ar), 7.66 (dt, $J = 7.7, 1.3$ Hz, 1H, H-Ar), 7.48 (t, $J = 7.9$ Hz, 1H, H-Ar), 7.34 – 7.20 (m, 3H, H-Ar), 7.16 – 6.99 (m, 2H, H-Ar), 4.68 (m, 1H, CH), 4.15 – 3.90 (m, 3H), 3.28 (dd, $J_{ab} = 13.5, J_{a14} = 7.0$ Hz, 1H), 3.14 (dd, $J_{ab} = 13.4, J_{a4} = 3.4$ Hz, 1H), 2.76 (dd, $J_{ba} = 13.5, J_{b14} = 7.6$ Hz, 1H), 2.62 (dd, $J_{ba} = 13.4, J_{b4} = 9.4$ Hz, 1H), 1.21 (d, $J = 6.7$ Hz, 2H, CH₃). ¹³C NMR (75 MHz, CDCl₃) δ (ppm) 175.6 (CO), 153.0, 148.3, 141.3, 139.6, 135.5, 134.9, 129.3 (2C), 128.9 (2C), 127.4, 124.1, 121.6, 66.1, 55.2, 39.5, 39.2, 37.8, 16.6 (CH₃). HPLC/MS: retention time 10.04 min $[M+H]^+ = 368$. Elemental analysis calcd. for C₂₀H₂₀N₂O₅: C, 65.21; H, 5.47; N, 7.60; found C, 65.50; H, 5.71; N, 7.83.

(R)-3-[(S)-3-(3-aminophenyl)-2-methylpropanoyl]-4-benzyloxazolidin-2-one (23). The catalytic hydrogenation of **22** (0.25 g, 0.68 mmol) in THF/AcOEt (1:2, 20 mL) adding Pd-C 10% cat. was carried out in mild conditions (21 psi., r.t.) in a PAR reactor over 12 h. Finally, the reaction mixture was filtered through a hydrophilic PVDF filter (30 mm, 0.45 μ) and the solvent removed under reduced pressure yielding **23** as an oil (0.21 g, 90%). $[\alpha]_D^{20} = -14.8$. ¹H NMR (300 MHz, CDCl₃) δ (ppm) 7.30 – 7.24 (m, 2H, H-Ar), 7.20 (m, 3H, H-Ar), 7.15 – 7.06 (m, 2H, H-Ar), 7.00 (m, 2H, H-Ar), 4.65 (m, 1H), 4.20 – 4.01 (m, 3H), 3.17 – 2.98 (m, 2H), 2.62 (m, 2H), 1.16 (d, $J = 6.8$ Hz, 3H, CH₃). ¹³C NMR (75 MHz, CDCl₃) δ (ppm) 176.4 (CO), 153.1 (CO),

140.8, 135.2, 135.2 (2C), 129.2 (2C), 128.9, 127.1, 120.5 (2C), 117.8, 66.0, 55.2, 39.6, 39.2, 37.5, 16.5 (CH₃). HPLC/MS: retention time 6.94 min [M+H]⁺= 338. Elemental analysis calcd. for C₂₀H₂₂N₂O₅: C, 70.99; H, 6.55; N, 8.28; found C, 71.04; H, 6.78; N, 8.19.

Pharmacological Evaluation.

In vivo food intake studies

The acute effects of drugs on feeding behavior were analyzed in 24-h food-deprived male Wistar rats weighing 300-350 g from Charles Rivers Laboratories España, S.A. (Barcelona, Spain). Animals were housed individually in cages in a temperature- and humidity-controlled room (22 °C and 55 % relative humidity) with a 12:12-h yellow light/dark cycle.

Water and food were available *ad libitum*. Animals were handled daily for a week before starting the experiments. The drugs were administered intraperitoneally (i.p.) at doses of 0.3, 1, and 3 mg/kg suspended in Tween 80 and saline as vehicle. After a period of 15 min after drug administration the animals were returned to their home cage and food intake was monitored 30, 60, 120 and 240 min after starting the test. In some cases the food intake was monitored after 24h. At the end of the test, the amount of water consumed was also measured. All animal procedures met the National Institutes of Health guidelines for the care and use of laboratory animals, and the European Communities directive 86/609/EEC regulating animal research.

Computational details

Theoretical calculations. All calculations were performed on an Intel® Core™2 Quad Workstation using Linux Ubuntu kernel 3.4.0.

Preparation of ligands and target macromolecule. ChemAxon Marvin 5.4.1 software package (2013) (<http://www.chemaxon.com>), accessed 09/10/2012) was used to build the structure of the ligands. Energy minimization and partial charges were calculated using PM6 method available in MOPAC 2012.²⁷

The three-dimensional structure of PPAR α -LBD (1K7L entry, chain A) and PPAR γ -LBD (1K74 entry, chain A) were retrieved from the RCSB Protein Data Bank.²⁸ Ligands, salts, and water molecules were removed, and the tautomeric forms were checked. In order to optimize hydrogen bond networks, the MolProbity server was used to add hydrogen atoms.²⁹ Finally, Kollman charges were computed through ADT.

To prepare the appropriate file needed for the docking study, non-polar hydrogen atoms were merged and rotatable bonds within the ligands were defined through AutoDockTools v1.5 (ADT) program (The Scripps Research Institute: <http://mgltools.scripps.edu/>, accessed 22/06/2012) (La Jolla, CA, USA).

Protocol for docking study. Protocol for docking study. Docking experiments of compounds were carried out by means of AutoDock v4 package.³⁰ For the calculations, a grid box with the dimensions 60x60x60 points was constructed around the binding site based on the location of the co-crystallized ligand GW409544 (1K7L entry, chain A) (1K74 entry, chain B), dimensions of axis were 22.5 Å and spacing of the grid points was 0.375 Å. The Lamarckian genetic algorithm (LGA) procedure was employed and the docking runs were set to 100, the maximum number of generations to 27,000 and the maximum number of energy evaluations to 25,000,000. The rest of the parameters were taken as default.

Analysis of the binding mode. To select the binding mode of each compound, we applied a qualitative analysis based on the location/orientation of the best 100 docked conformations given

by AutoDock in relation to the co-crystallized ligand GW409544.³¹ Hydrogen bonds and properties in ligand-receptor interaction of the binding mode of each compound were evaluated by using Accelrys Discovery Studio® v2.0 (Accelrys, Inc., San Diego, CA, USA). Measurements of docked conformations RMSD were carried out through ADT.

ASSOCIATED CONTENT

Supporting Information.

AUTHOR INFORMATION

Corresponding Authors:

R.P.-F.: E-mail: ruth.perez@csic.es. Phone +34 918373112

M.M.-G.: E-mail: mmacias.manuel@gmail.com. Phone: +34951032648

ACKNOWLEDGMENT

This work was supported by SAF2012-40075-C02-02, RTA (RED Trastornos Adictivos UE-FEDER/EU-ERDF RD06/001/0014 and RD12/028/001), Centros de Investigación En Red (CIBER, CB06/03/0018) of the “Instituto de Salud Carlos III” (ISCIII) and PI11/0166 and PI113/02261 from the ISCIII. MMG and PRF were recipient of the Nicolas Monardes program from the Servicio Andaluz de Salud, Junta de Andalucía, Spain (C-0029-2014).

ABBREVIATIONS

PPAR, peroxisome proliferator activated receptors; LBD, ligand binding domain; AF, activation factor; HB, hydrogen bond.

REFERENCES

1. Wright, M.B.; Bortolini, M.; Tadayyon, M.; Bopst, M. Challenges and Opportunities in Development of PPAR Ligands. *Mol. Endocrinol.* **2014**, *28*, 1756-1758.
2. Liu, Z.-M.; Hu, M.; Chan, P.; Tomlinson, B. Early Investigational Drugs Targeting PPAR α for the Treatment of Metabolic Disease. *Expert Opin. Investig. Drugs* **2015**, *24*, 1-11.
3. Agrawal, R. The First Approved Agent in the Glitazar's Class: Saroglitazar. *Curr. Drug Targets* **2014**, *15*, 151-155.
4. Pirat, C.; Farce, A.; Lebègue, N.; Renault, N.; Furman, C.; Millet, R.; Yous, S.; Speca, S.; Berthelot, P.; Desreumaux, P.; Chavatte, P. Targeting PPARs: Development of Modulators. *J. Med. Chem.* **2012**, *55*, 4027-4061.
5. Goya, P.; Pérez-Fernández, R.; González-Muñiz, R.; Elguero, J. Enantioselective Synthesis of PPAR Agonists and Antagonists. *Curr. Top. Med. Chem.* **2014**, *14*, 1283-1293 and references herein.
6. Laghezza, A.; Pochetti, G.; Lavecchia, A.; Fracchiolla, G.; Faliti, S.; Piemontese, L.; Di Giovanni, C.; Lacobazzi, V.; Infantino, V.; Montanari, R.; Capelli, D.; Tortorella, P.; Loiodice, F. s New 2-(Aryloxy)-3-phenylpropanoic Acids as Peroxisome Proliferator-Activated Receptor α/γ Dual Agonists Able to Upregulate Mitochondrial Carnitine Shuttle System Gene Expression. *J. Med. Chem.* **2013**, *56*, 60-72.

- 1
2
3 7. Kuwabara, N.; Oyama, T.; Tomioka, D.; Ohashi, M.; Yanagisawa, J.; Shimizu, T.; Miyachi,
4
5 H. PPARs Have Multiple Binding Points that Accommodate Ligands in Various Conformations:
6
7 Phenylpropanoic Acid-type PPAR Ligands Bind to PPAR in Different Conformations,
8
9 Depending on the Subtype. *J. Med. Chem.* **2012**, *55*, 893-902.
10
11
12
13
14 8. Nevin, D. K.; Peters, M. B.; Carta, G.; Fayne, D.; Lloyd, D. G. Integrated Virtual Screening
15
16 for the Identification of Novel and Selective PPAR Scaffolds. *J. Med. Chem.* **2012**, *55*, 4978-
17
18 4989.
19
20
21
22 9. Heravi, M. M.; Zadsirjan, V. Oxazolidinones as Chiral Auxiliaries in Asymmetric Aldol
23
24 Reactions Applied to Total Synthesis. *Tetrahedron: Asymmetry* **2013**, *24*, 1149-1188.
25
26
27
28 10. Pandit, N.; Singla, R. K.; Shrivastava, B. Current Updates on Oxazolidinone and its
29
30 Significance. *Int. J. Med. Chem.* **2012**, 159285, 24pp.
31
32
33
34 11. Suzuki, H.; Utsunomiya, I.; Shudo, K.; Fujimura, T.; Tsuji, M.; Kato, I.; Aoki, T.; Ino, A.;
35
36 Iwaki, T. Potent Oxazolidinone Antibacterials with Heteroaromatic C-ring Substructure. *ACS*
37
38 *Med. Chem. Lett.* **2013**, *4*, 1074-1078.
39
40
41
42 12. Reddy, G. S. K. K.; Ali, A.; Nalam, M. N. L.; Anjum, S. G.; Cao, H.; Nathans, R. S.;
43
44 Schiffer, C. A.; Rana, T. M. Design and Synthesis of HIV-1 Protease Inhibitors Incorporating
45
46 Oxazolidinones as P2/P2' Ligands in Pseudosymmetric Dipeptide Isosteres. *J. Med. Chem.* **2007**,
47
48 *50*, 4316-4328.
49
50
51
52 13. Ohashi, M.; Nakagome, I.; Kasuga, J. -I.; Nobusada, H.; Matsuno, K.; Makishima, M.;
53
54 Hirono, S.; Hashimoto, Y.; Miyachi, H. Design, Synthesis and in Vitro Evaluation of a Series of
55
56
57
58
59
60

- 1
2
3
4 α -Substituted Phenylpropanoic Acid PPAR γ Agonists to Further Investigate the
5
6 Stereochemistry-Activity Relationship. *Bioorg. Med. Chem.* **2012**, *20*, 6375-6383.
7
8
9
10 14. Nomura, M.; Tanase, T.; Miyachi, H. Efficient Asymmetric Synthesis of (S)-2-
11
12 Ethylphenylpropanoic Acid Derivative, a Selective Agonist for Human PPAR α . *Bioorg. Med.*
13
14 *Chem Lett.* **2002**, *12*, 2101-2104.
15
16
17 15. Kasuga, J. -I.; Hashimoto, Y.; Miyachi, H. Concise and Efficient Asymmetric Synthesis of
18
19 (S)-2-Ethylphenylpropanoic Acid Derivatives: Dual Agonists for Human PPAR α and γ . *Bioorg.*
20
21 *Med. Chem. Lett.* **2006**, *16*, 771-774.
22
23
24
25 16. Agrawal, A. K.; Hop, C. E. C. A.; Pang, J.; Elipe, M. V. S.; Desai, R. C.; Leung, K. H.;
26
27 Franklin, R. B. In Vitro Metabolism of a New Oxazolidinedione Hypoglycemic Agent Utilizing
28
29 Liver Microsomes and Recombinant Human Cytochrome P450 Enzymes. *J. Pharm. Biomed.*
30
31 *Anal.* **2005**, *37*, 351-358.
32
33
34
35 17. Pérez-Fernández, R.; Fresno López, M. N.; Elguero Bertolini, J.; Goya Laza, P.; Torres
36
37 Zaguire, A. B.; Rodríguez de Fonseca, F.; Pavón Morón, F J.; Macías González, M.; Romero
38
39 Cuevas, M. "Oxazolidinone Derivatives as PPAR Ligands" Patent WO2015004306.
40
41
42
43 18. Xu, H. E.; Lambert, M. H.; Montana, V. G.; Plunket, K. D.; Moore, L. B.; Collins, J. L.;
44
45 Oplinger, J. A.; Kliewer, S. A.; Gampe Jr, R. T.; McKee, D. D. Structural Determinants of
46
47 Ligand Binding Selectivity Between the PPARs *Proc. Natl. Acad. Sci. USA* **2001**, *98*, 13919.
48
49
50
51 19. Decara, J.M.; Romero-Cuevas, M.; Rivera, P.; Macias-González, M.; Vida, M.; Pavón, F.J.;
52
53 Serrano, A.; Cano, C.; Fresno, N.; Pérez-Fernández, R.; Rodríguez de Fonseca, F.; Suárez, J.
54
55
56
57
58
59
60

Elaidyl-sulfamide, an Oleoylethanolamide-modelled PPAR α Agonist, Reduces Body Weight Gain and Plasma Cholesterol in Rats. *Dis. Model Mech.* **2012**, *5*, 660-70.

20. Fresno, N.; Pérez-Fernández, R.; Goya, P.; Jimeno, M. L.; Alkorta, I.; Elguero, J.; Menéndez-Taboada, L.; García-Granda, S. Oxazolidinone Cross-alkylation During Evans' Asymmetric Alkylation Reaction *Tetrahedron* **2011**, *67*, 9104-9111.

21. Cano, C.; Pavón, J.; Serrano, A.; Goya, P.; Páez, J. A.; Rodríguez de Fonseca, F.; Macías-González, M. Novel Sulfamide Analogs of Oleoylethanolamide Showing in Vivo Satiety Inducing Actions and PPAR α Activation. *J. Med. Chem.* **2007**, *50*, 389-393.

22. Cardona, F.; Morcillo, S.; Gonzalo-Marín, M.; Garrido-Sánchez, L.; Macías-González, M.; Tinahones, F. J. Pro12Ala Sequence Variant of the PPAR γ gene Is Associated with Postprandial Hypertriglyceridemia in Non-E3/E3 Patients with Metabolic Syndrome. *Clin. Chem.* **2006**, *52*, 1920-1925.

23. Macías-González, M.; Cardona, F.; Queipo-Ortuño, M.; Bernal, R.; Martín, M.; Tinahones, F. J. PPAR γ mRNA Expression Is Reduced in Peripheral Blood Mononuclear Cells after Fat Overload in Patients with Metabolic Syndrome. *J. Nutr.* **2008**, *138*, 903-907.

24. Pérez-Fernández, R.; Fresno, N.; Macías-González, M.; Elguero, J.; Decara, J.; Girón, R.; Rodríguez-Alvarez, A.; Martín, M. I.; Rodríguez de Fonseca, F.; Goya, P. Discovery of Potent Dual PPAR α Agonists/CB1 Ligands. *ACS Med. Chem. Lett.* **2011**, *2*, 793-797.

25. Alvarado, M.; Goya, P.; Macías-González, M.; Pavón, F. J.; Serrano, A.; Jagerovic, N.; Elguero, J.; Gutiérrez-Rodríguez, A.; García-Granda, S.; Suardíaz, M.; Rodríguez de Fonseca, F.

- 1
2
3 Antiobesity Designed Multiple Ligands: Synthesis of Pyrazole Fatty Acid Amides and
4
5 Evaluation as Hypophagic Agents. *Bioorg. Med. Chem. Lett.* **2008**, *16*, 10098.
6
7
8
9 26. Serrano, A.; del Arco, I.; Pavón, J.; Macías-González, M.; Pérez-Valero, V.; Rodríguez de
10
11 Fonseca, F. The Cannabinoid CB1 Receptor Antagonist SR141716A (Rimonabant) Enhances the
12
13 Metabolic Benefits of Long-term Treatment with Oleyethanolamide in Zucker Rats.
14
15 *Neuropharmacology* **2008**, *54*, 226-234.
16
17
18
19 27. MOPAC2012, James J. P. Stewart, Stewart Computational Chemistry, Colorado Springs,
20
21 CO, USA, <http://OpenMOPAC.net/> (2012).
22
23
24
25 28. H.M. Berman, J. Westbrook, Z. Feng, G. Gilliland, T.N. Bhat, H. Weissig, I.N. Shindyalov,
26
27 P.E. Bourne. The Protein Data Bank. *Nucleic Acids Research*, 200, 28: 235-242.
28
29
30
31 29. Vincent B. Chen, W. Bryan Arendall III, Jeffrey J. Headd, Daniel A. Keedy, Robert M.
32
33 Immormino, Gary J. Kapral, Laura W. Murray, Jane S. Richardson and David C. Richardson
34
35 (2010) MolProbity: All-atom Structure Validation for Macromolecular Crystallography. *Acta*
36
37 *Crystallogr. Sect. A*, **2010**, D66: 12-21.
38
39
40
41 30. Morris, G. M.; Goodsell, D. S.; Halliday, R. S.; Huey, R.; Hart, W. E.; Belew, R. K.; Olson,
42
43 A. J. Automated Docking Using a Lamarckian Genetic Algorithm and Empirical Binding Free
44
45 Energy Function. *J. Comput. Chem.* **1998**, *19*, 1639–1662.
46
47
48
49 31. Ali, H. I.; Tomita, K.; Akaho, E.; Kunishima, M.; Kawashima, Y.; Yamagishi, T.; Ikeya, H.,
50
51 Nagamatsu, T. Antitumor Studies – part 2, Structure-Activity Relationship Study for Flavin
52
53 Analogs Including Investigations on their In Vitro Antitumor Assay and Docking Simulation into
54
55 Protein Tyrosine Kinase. *Eur. J. Med. Chem.* **2008**, *43*, 1376–1389.
56
57
58
59
60

Table of Contents Graphic